

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bernd RIEDL et al.

Confirmation No.: 3172

Serial No.: 10/086,417

Examiner: Henley III, Raymond J

Filed: March 4, 2002

Group Art Unit: 1614

Title: OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38
KINASE INHIBITORS

SUPPLEMENTAL REPLY AND
INFORMATION DISCLOSURE STATEMENT

MAIL STOP NON FINAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Further to the Response filed on December 8, 2006 (copy attached), Applicants submit this Supplemental Reply and Information Disclosure Statement.

A copy of the claims in the following co-pending application is attached.

09/889,227
10/071,248
09/948,915
10/361,858
09/993,647
10/042,203
10/361,859
10/308,187
10/895,985

Applicants have resubmitted the references AA-BM on pages 6-8 of the PTO-1449 form filed October 4, 2005. The Examiner indicated copies of these references could not be located on the disc provided and struck through them on the PTO-1449 Form.

Respectfully submitted,



Richard J. Traverso, Reg. No. 30,595
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO &
BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER-0016-P04

Date: December 15, 2006

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


1. (Currently Amended) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is $-\text{NH}-\text{C}(\text{O})-\text{NH}-$,

A is a substituted moiety of the formula:



wherein L is phenyl, optionally substituted by halogen, up to per-halo, and W_n , where n is 0-3;

wherein each W is independently selected from the group consisting of C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched haloalkyl up to perhaloalkyl and C_1 - C_3 alkoxy L^1 is selected from pyridinyl substituted by $-\text{C}(\text{O})\text{R}_x$, and

optionally substituted with 1-3 additional substituents independently selected from the group consisting of R^7 and halogen;

wherein R_x is NR_aR_b and R_a and R_b are

A) independently

- a) hydrogen,
- b) C_1 - C_{10} alkyl,
- c) C_6 aryl,
- d) pyridinyl
- e) substituted C_{1-10} alkyl,

§ Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

- f) substituted C₆ aryl,
- g) substituted pyridinyl
- h) -phenylpiperazine(pyridinyl),
- i) -phenylmorpholinyl,
- j) -ethylmorpholinyl,
- k) -ethylpiperidyl,
- l) -methyl pyrrolidinyl,
- m) -methyl tetrahydrofuryl,
- or
- n) -C₂H₄NH(phenyl);

where when R_a and R_b are a substituted group, they are substituted by

- a) halogen up to per halo,
 - b) hydroxy,
 - c) -N(CH₃)₂,
 - d) C₁-C₁₀ alkyl,
 - e) C₁-C₁₀ alkoxy,
 - f) halosubstituted C₁₋₆ alkyl, or
 - g) -OSi(Pr-i)₃; or
- B) R_a and R_b together form piperazine or a substituted piperazine with substituents selected from the group consisting of
- a) halogen,
 - b) hydroxy,
 - c) C₁₋₁₀ alkyl,
 - d) pyridinyl
 - e) C₁₋₁₀ alkoxy,

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

- f) C₆ aryl,
- h) g) halo substituted C₆ aryl, and
- i) h) N-(4-acetylphenyl);

M is selected from the group consisting of oxygen and sulfur;

and

B is

phenyl, substituted with 1-3 substituents independently selected from the group consisting of halogen and R⁷,

and R⁷ is

- (a) C₁-C₆ linear or branched alkyl, optionally substituted with 1-3 halogen substituents; or
- (b) C₁-C₆ linear or branched alkoxy.

2. (Canceled)

3. (Previously Presented) A compound as in claim 1 wherein M is oxygen .

4. (Previously Presented) A compound as in claim 1 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

5. (Canceled)

6. (Currently Amended) A compound of claim 1 wherein B of Formula I is phenyl, substituted with 1-3 substituents independently selected from the group consisting of halogen chlorine, C₁-C₆ alkoxy or up to per halo substituted C₁-C₆ alkyl.

7. (Currently Amended) A compound of claim 3 wherein B of Formula I is

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

phenyl, substituted with 1-3 substituents independently selected from the group consisting of ~~halogen~~
chlorine, C₁-C₆ alkoxy, or substituted C₁-C₆ alkyl, substituted by one or more halogen substituents.

8. **(Currently Amended)** A compound of claim 4 wherein B of Formula I is phenyl, substituted 1 to 3 times by 1 or more substituents selected from the group consisting of ~~halogen~~
chlorine, C₁-C₆ alkoxy or up to per halo substituted C₁-C₆ alkyl.

9. **(Previously Presented)** A compound of claim 1, wherein L is phenyl, optionally substituted by halogen up to perhalo.

10. **(Previously Presented)** A compound of claim 1, wherein L is phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of halogen and C₁-C₃ alkoxy.

11. **(Canceled)**

12. **(Canceled)**

13. **(Canceled)**

14. **(Canceled)**

15. **(Canceled)**

16. **(Canceled)**

17. **(Canceled)**

18. **(Previously Presented)** A compound of claim 4, wherein M is -O-.

19. **(Previously Presented)** A compound of claim 8 wherein M is -O-.

20. **(Previously Presented)** A compound of claim 9 wherein M is -O-.

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

21. **(Previously Presented)** A compound of claim 10 wherein M is -O-.
22. **(Previously Presented)** A compound of claim 1 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1 - C_6 alkyl, halogen and C_1 - C_6 alkoxy.
23. **(Previously Presented)** A compound of claim 3 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1 - C_6 alkyl, halogen and C_1 - C_6 alkoxy.
24. **(Previously Presented)** A compound of claim 18 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1 - C_6 alkyl, halogen and C_1 - C_6 alkoxy.
25. **(Previously Presented)** A compound of claim 19 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1 - C_6 alkyl, halogen and C_1 - C_6 alkoxy.
26. **(Previously Presented)** A compound of claim 20 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1 - C_6 alkyl, halogen and C_1 - C_6 alkoxy.
27. **(Previously Presented)** A compound of claim 21 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1 - C_6 alkyl, halogen and C_1 - C_6 alkoxy.

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

28. (Canceled)

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Canceled)

33. (Previously Presented) A compound of claim 3 wherein R_a and R_b are independently hydrogen or C_1 - C_6 alkyl.

34. (Previously Presented) A compound of claim 18 wherein R_a and R_b are independently hydrogen or C_1 - C_6 alkyl.

35. (Previously Presented) A compound of claim 19 wherein R_a and R_b are independently hydrogen or C_1 - C_6 alkyl.

36. (Previously Presented) A compound of claim 20 wherein R_a and R_b are independently hydrogen or C_1 - C_6 alkyl.

37. (Previously Presented) A compound of claim 21 wherein R_a and R_b are independently hydrogen or C_1 - C_6 alkyl.

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

38. (Previously Presented) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is $-\text{NH}-\text{C}(\text{O})-\text{NH}-$,

A is of the formula: $-\text{L}-\text{M}-\text{L}^1$, wherein

L is phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched haloalkyl up to perhalo, C_1 - C_3 alkoxy and halogen;

L^1 is pyridinyl, substituted by $-\text{C}(\text{O})\text{R}_x$;

wherein R_x is NR_aR_b and R_a and R_b are independently

hydrogen,

C_1 - C_{10} alkyl,

C_6 aryl,

pyridinyl, substituted C_{1-10} alkyl,

substituted C_6 aryl, or

substituted pyridinyl,

where R_a and R_b are a substituted group, they are substituted by halogen up to per halo; and

M is selected from the group consisting of oxygen and sulfur

and

B is phenyl, substituted with 1-3 substituents independently selected from the group consisting of R^7 and halogen;

and R^7 is

(a) C_1 - C_6 linear or branched alkyl, optionally substituted with 1-3 halogen substituents; or

(b) C_1 - C_6 linear or branched alkoxy.

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

39. (Previously Presented) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is $-\text{NH}-\text{C}(\text{O})-\text{NH}-$,

A is of the formula: $-\text{L}-\text{M}-\text{L}^1$,

L is phenyl,

M is $-\text{O}-$,

L^1 is pyridinyl substituted by $-\text{C}(\text{O})\text{R}_x$,

wherein R_x is NR_aR_b and R_a and R_b are independently
hydrogen,

C_1 - C_{10} alkyl,

C_6 aryl,

pyridinyl,

substituted C_{1-10} alkyl,

substituted C_6 aryl, or

substituted pyridinyl

where R_a and R_b are a substituted group, they are substituted by halogen up to per halo,
and

B is a phenyl group substituted by trifluoromethyl or tert-butyl, and optionally additional
substituents selected from the group consisting of halogen up to per halo, and W_n where n is 0-3, and
each W is independently selected from the group consisting of

C_1 - C_{10} alkyl,

C_1 - C_{10} alkoxy,

C_6 aryl,

pyridinyl.

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

and substituted C₁-C₁₀ alkyl, substituted by one or more substituents independently selected from the group consisting of halogen up to per halo.

40. **(Previously Presented)** A compound as in claim 38 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

41. **(Canceled)**

42. **(Previously Presented)** A compound as in claim 39 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

43. **(Canceled)**

44. **(Previously Presented)** A compound as in claim 38 wherein substituents for B₁ are selected from the group consisting of up to per halo substituted C₁-C₆ alkyl and halogen.

45. **(Previously Presented)** A compound as in claim 39 wherein the optional substituents for B are selected from the group consisting of up to per halo substituted C₁-C₆ alkyl and halogen.

46. **(Canceled)**

47. **(Canceled)**

48. **(Canceled)**

49. **(Canceled)**

50. **(Previously Presented)** A pharmaceutically acceptable salt of a compound of formula I of claim 1 which is

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

51. (Cancelled)

52. (Canceled)

53. (Previously Presented) A pharmaceutically acceptable salt of a compound of claim 38 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

54. (Previously Presented) A pharmaceutically acceptable salt of a compound of claim 39 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

55. (Previously Presented) A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

56. (Canceled)

57. (Canceled)

58. (Previously Presented) A pharmaceutical composition comprising a compound of formula I of claim 38 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

59. (Previously Presented) A pharmaceutical composition comprising a compound of formula I of claim 39 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

60. (Canceled)

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

61. (Cancelled)

62. (Currently Amended) A method for inhibiting the enzyme raf kinase in a human or animal, comprising administering a pharmaceutically acceptable amount of a compound of Formula I of claim 1 to said mammal.

63. (Canceled)

64. (Currently Amended) A method for inhibiting the enzyme raf kinase in a human or animal, comprising administering a pharmaceutically acceptable amount of a compound of Formula I of claim 38 to said mammal.

65. (Currently Amended) A method for inhibiting the enzyme raf kinase in a human or animal, comprising administering a pharmaceutically acceptable amount of a compound of Formula I of claim 39 to said mammal.

66. (Canceled)

67. (Canceled)


68. (Previously Presented) A compound of claim 1 wherein the optional substituents on L¹ are selected from the group consisting of methyl, trifluoromethyl, methoxy, Cl and F.

69. (Previously Presented) A compound of claim 1 wherein the substituents of B and L are independently selected from the group consisting of methyl, trifluoromethyl, tert-butyl, methoxy, Cl, and F.

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

70. (Currently Amended) A pharmaceutical composition ~~for the treatment of a cancerous cell growth~~ comprising a compound of formula I of claim 1 or a pharmaceutically acceptable salt of a compound of formula I and a physiologically acceptable carrier.

71. (Previously Presented) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is $-\text{NH}-\text{C}(\text{O})-\text{NH}-$,

A is a substituted moiety of the formula: $-\text{L}-\text{M}-\text{L}^1$,

wherein L is phenyl, optionally substituted with substituents independently selected from the group consisting of halogen, $\text{C}_1\text{-C}_5$ alkyl, $\text{C}_1\text{-C}_5$ alkyl substituted by halogen and $\text{C}_1\text{-C}_5$ alkoxy;

L^1 is pyridinyl, substituted with $-\text{C}(\text{O})\text{NR}^a\text{R}^b$ and optionally substituted with one or two substituents selected from the group consisting of R^7 , OR^7 and halogen, wherein R^7 is hydrogen, $\text{C}_1\text{-C}_5$ alkyl or $\text{C}_1\text{-C}_5$ alkyl substituted by halogen,

wherein R^a and R^b independently are

- a) hydrogen or
- b) $\text{C}_1\text{-C}_5$ alkyl;

B is phenyl, substituted by tert-butyl or trifluoromethyl and optionally substituted with additional substituents independently selected from the group consisting of

- a) halogen,
- b) $\text{C}_1\text{-C}_5$ alkyl substituted by halogen or
- c) $\text{C}_1\text{-C}_4$ alkoxy.

§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

72. **(Currently Amended)** A pharmaceutical composition for the treatment of a cancerous cell growth as in claim ~~74~~ 70 wherein the pharmaceutically acceptable salt is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

- 73. **(Canceled)**
- 74. **(Canceled)**
- 75. **(Canceled)**
- 76. **(Canceled)**
- 77. **(Canceled)**
- 78. **(Canceled)**
- 79. **(Canceled)**
- 80. **(Canceled)**
- 81. **(Canceled)**
- 82. **(Canceled)**
- 83. **(Canceled)**
- 84. **(Canceled)**
- 85. **(Canceled)**


§Appl. No. 09/889,227
Amdt. dated October 25, 2006
Reply to Office Action of, May 25, 2006

- 86. (Canceled)
- 87. (Canceled)
- 88. (Canceled)
- 89. (Cancelled)

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Original) A compound of formula (Ia)



wherein,

Y is NHR,

Hal is chlorine or bromine,

R is H, CH₃ or CH₂OH, and


X¹ to X⁷ are each, independently, H, OH or -OC(O)C₁-C₄ alkyl,

or a salt or purified stereoisomer thereof,

with the proviso that at least one of X¹ to X⁷ is OH or -OC(O)C₁-C₄ alkyl.

2. (Original) A compound of claim 1 wherein X¹ is OH or -OC(O)C₁-C₄ alkyl.
3. (Original) A compound of claim 1 wherein X² is OH or -OC(O)C₁-C₄ alkyl.
4. (Original) A compound of claim 1 wherein X³ is OH or -OC(O)C₁-C₄ alkyl.
5. (Original) A compound of claim 1 wherein X⁴ is OH or -OC(O)C₁-C₄ alkyl.
6. (Original) A compound of claim 1 wherein X⁵ is OH or -OC(O)C₁-C₄ alkyl.

7. (Original) A compound of claim 1 wherein X^6 is OH or $-OC(O)C_1-C_4$ alkyl.
8. (Original) A compound of claim 1 wherein X^7 is OH or $-OC(O)C_1-C_4$ alkyl.
9. (Original) A compound of claim 1 wherein Hal is chlorine.
10. (Original) A compound of claim 1 which is 4-{4-[[[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl]amino]2-(hydroxy)phenoxy}-2-pyridine carboxamide.
11. (Original) A compound of claim 1 which is 4-{4-[[[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl]amino]3-(hydroxy)phenoxy}-2-pyridine carboxamide.
12. (Original) A compound of claim 1 which is 4-{4-[[[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl]amino]5-(hydroxy)phenoxy}-2-pyridine carboxamide.
13. (Original) A compound of claim 1 which is 4-{4-[[[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl]amino]6-(hydroxy)phenoxy}-2-pyridine carboxamide.
14. (Original) A compound of formula (Ib)



wherein,

Y is NHR,

Hal is chlorine or bromine,


R is H, CH₃ or CH₂OH, and

X⁴ to X⁷ are each, independently, H, OH or -OC(O)C₁-C₄ alkyl,

or a salt or purified stereoisomer thereof,

with the proviso that at least one of X⁴ to X⁷ is OH or -OC(O)C₁-C₄ alkyl.

15. (Currently Amended) A compound of formula (Ic)



wherein,

Hal is chlorine or bromine, and

X¹ to X⁷ are each, independently, H, OH or -OC(O)C₁-C₄ alkyl,

or a salt or purified stereoisomer thereof,

with the proviso that at least one of X¹ to X⁷ is OH or -OC(O)C₁-C₄ alkyl.

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

- 20. (Cancelled)
- 21. (Cancelled)
- 22. (Previously Presented) A method of treating osteoporosis and inflammation, in a mammal by administering an effective amount of a compound of claim 1 to said mammal.
- 23. (Cancelled)
- 23. (Cancelled)
- 24. (Cancelled)
- 25. (Cancelled)

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

I. (Currently Amended) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is $-\text{NH}-\text{C}(\text{O})-\text{NH}-$,

A is a substituted moiety of up to 40 carbon atoms of the formula: $-\text{L}-(\text{M}-\text{L}^1)_q$, where L is a 6 membered cyclic structure, which is substituted phenyl or unsubstituted phenyl, bound directly to D, L^1 comprises a substituted cyclic moiety having at least 5 members which is phenyl or pyridinyl,

M is a bridging group which comprises ~~comprise~~ $-\text{O}-$, $-\text{S}-$, or $-\text{NR}^7-$ $-\text{N}(\text{R}^7)-$, wherein R^7 is hydrogen, q is an integer of from 1-3; and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D which is phenyl or pyridinyl,

wherein L^1 is substituted by $-\text{C}(\text{O})\text{R}_x$,

R_x is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 heteroatoms, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_3-C_{12} hetaryl having 1-3 heteroatoms selected from, S, N and O, C_{7-24} alkaryl, C_{7-24} or aralkyl, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halo substituted alkyl up to per halo alkyl, C_6-C_{12} halo substituted aryl up to per halo aryl, C_3-C_{12} halo substituted cycloalkyl up to per halo cycloalkyl having 0-3 heteroatoms selected from N, S and O, halo substituted C_3-C_{12} hetaryl up to per halo hetaryl having 1-3 heteroatoms selected from O, N

and S, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, or -C(O)R_g;

R_x is R_z or NR_aR_b where R_a and R_b are

a) independently hydrogen,

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₃-C₁₀ cycloalkyl, C₂-C₁₀ alkenyl, C₁-C₁₀ alkenoyl, C₆-C₁₂ aryl, C₃-C₁₂ hetaryl having 1-3 heteroatoms selected from O, N and S, C₃-C₁₂ cycloalkyl having 0-3 heteroatoms selected from N, S and O, C₇-C₂₄ aralkyl, or C₇-C₂₄ alkaryl, and is optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁-C₁₀ alkyl, C₃-C₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃-C₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁-C₁₀ alkoxy, C₆-C₁₂ aryl, C₁-C₆ halo substituted alkyl up to per halo alkyl, C₆-C₁₂ halo substituted aryl up to per halo aryl, C₃-C₁₂ halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo hetaryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, or -C(O)R_g and are optionally substituted by halogen, or

-OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₆-C₁₂ aryl, C₃-C₁₂ hetaryl having 1-3 heteroatoms selected from O, S and N, or C₇-C₂₄ aralkyl, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁-C₁₀ alkyl, C₃-C₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃-C₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁-C₁₀ alkoxy, C₆-C₁₂ aryl, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, C₁-C₆ halo substituted alkyl up to per halo alkyl, C₆-C₁₂ halo substituted aryl up to per halo aryl, C₃-C₁₂ halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo hetaryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, or -C(O)R_g, or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, optionally substituted by halogen, hydroxy or carbon

based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C_{7-C24} alkaryl, C_{7-C24} aralkyl, halo substituted C₁₋₆ alkyl up to per halo alkyl, halo substituted C_{6-C12} aryl up to per halo aryl, halo substituted C_{3-C12} cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_{3-C12} hetaryl up to per halo hetaryl, halo substituted C_{7-C24} aralkyl up to per halo aralkyl, halo substituted C_{7-C24} alkaryl up to per halo alkaryl, or -C(O)R_g, or

c) one of R_a or R_b is -C(O)-, a C_{1-C5} divalent alkylene group or a substituted C_{1-C5} divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_{1-C5} divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C_{7-C24} alkaryl, C_{7-C24} aralkyl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C_{6-C12} halo substituted aryl up to per halo aryl, C_{3-C12} halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_{3-C12} hetaryl up to per halo hetaryl, halo substituted C_{7-C24} aralkyl up to per halo aralkyl, halo substituted C_{7-C24} alkaryl up to per halo alkaryl, or -C(O)R_g,

where B is substituted, L is substituted or L¹ is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W_n, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)NR⁷R⁷, -C(O)-R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which are C_{1-C10} alkyl, C_{1-C10} alkoxy, C_{2-C10} alkenyl, C_{1-C10} alkenoyl, C_{3-C10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{6-C14} aryl, C_{7-C24} alkaryl, C_{7-C24} aralkyl, C_{3-C12} heteroaryl having 1-3 heteroatoms selected from O, N and S, or C_{4-C23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NR⁷R⁷, -NO₂, -NR⁷C(O)R⁷, -NR⁷C(O)OR⁷

and halogen up to per-halo; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which are C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, C_2 - C_{10} alkenyl, C_1 - C_{10} alkenoyl, C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_6 - C_{14} aryl, C_3 - C_{13} hetaryl having 1-3 heteroatoms selected from O, N and S, C_7 - C_{14} alkaryl, C_7 - C_{24} aralkyl, or C_4 - C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by halogen,

wherein Q is -O-, -S-, -N(R^7)-, $-(CH_2)_m$ -, -C(O)-, -CH(OH)-, $-(CH_2)_mO$ -, $-(CH_2)_mS$ -, $-(CH_2)_mN(R^7)$ -, $-O(CH_2)_m$ -, $-CHX^a$ -, $-CX^a_2$ -, -S- $(CH_2)_m$ - and -N(R^7)(CH_2) $_m$ -, where $m = 1-3$, and X^a is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{n1} , wherein $n1$ is 0 to 3 and each Z is independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which is C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, C_2 - C_{10} alkenyl, C_1 - C_{10} alkenoyl, C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, C_6 - C_{14} aryl, or C_3 - C_{13} hetaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by one or more substituents selected from the group consisting of -CN, $-CO_2R^7$, $-COR^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NO_2$, $-NR^7R^7$, $-NR^7C(O)R^7$, and $-NR^7C(O)OR^7$, with R^7 as defined above

where R_g is C_{1-10} alkyl; -CN, $-CO_2R_d$, $-OR_d$, $-SR_d$, $-NO_2$, $-C(O)R_e$, $-NR_dR_e$, $-NR_dC(O)OR_e$ and $-NR_dC(O)R_e$, and R_d and R_e are independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, C_{6-12} aryl, C_3 - C_{12} hetaryl with 1-3 heteroatoms selected from O, N and S and C_7 - C_{24} aralkyl, C_7 - C_{24} alkaryl, up to per halo substituted C_1 - C_{10} alkyl, up to per halo substituted C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per halo substituted C_6 - C_{14} aryl, up to per halo substituted C_3 - C_{12} hetaryl having 1-3 heteroatoms selected from O, N, and S, halo substituted C_7 - C_{24} alkaryl up to per halo alkaryl, and up to per halo substituted C_7 - C_{24} aralkyl.

2. (Original) A compound as in claim 1 wherein:

R_y is hydrogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₃₋₁₀ cycloalkyl having 0-3 heteroatoms, C₂₋₁₀ alkenyl, C₁₋₁₀ alkenoyl, C₆₋₁₂ aryl, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₇₋₂₄ aralkyl, C₇₋₂₄ alkaryl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkoxy, substituted C₃₋₁₀ cycloalkyl having 0-3 heteroatoms selected from N, S and O, substituted C₆₋₁₄ aryl, substituted C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, substituted C₇₋₂₄ alkaryl or substituted C₇₋₂₄ aralkyl, where R_y is a substituted group, it is substituted by halogen up to per halo,

R_z is hydrogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₃₋₁₀ cycloalkyl having 0-3 heteroatom, C₂₋₁₀ alkenyl, C₁₋₁₀ alkenoyl, C₆₋₁₂ aryl, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from, S, N and O, C₇₋₂₄ alkaryl, C₇₋₂₄ aralkyl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkoxy, substituted C₆₋₁₄ aryl, substituted C₃₋₁₀ cycloalkyl having 0-3 heteroatoms selected from S, N and O, substituted C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from S, N and O, substituted C₇₋₂₄ alkaryl or substituted C₇₋₂₄ aralkyl where R_z is a substituted group, it is substituted by halogen up to per halo, hydroxy, C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C₆₋₁₂ halo substituted aryl up to per halo aryl, C₃₋₁₂ halo substituted cycloalkyl up to per halo cycloalkyl having 0-3 heteroatoms selected from N, S and O, halo substituted C₃₋₁₂ hetaryl up to per halo hetaryl having 1-3 heteroatoms selected from O, N and S, halo substituted C₇₋₂₄ aralkyl up to per halo aralkyl, halo substituted C₇₋₂₄ alkaryl up to per halo alkaryl, and -C(O)R_g,

R_a and R_b are,

a) independently hydrogen,

a carbon based moiety selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₃₋₁₀ cycloalkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkenoyl, C₆₋₁₂ aryl, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from O, N and S, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from N, S and O, C₇₋₂₄ aralkyl, C₇₋₂₄ alkaryl, substituted C₁₋₁₀ alkyl, substituted C₁₋₁₀ alkoxy, substituted C₃₋₁₀ cycloalkyl, having 0-3 heteroatoms selected from N, S and O, substituted C₆₋₁₂ aryl, substituted C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, substituted C₇₋₂₄ aralkyl, substituted C₇₋₂₄ alkaryl, where R_a and R_b are a substituted group, they are substituted by halogen up to per halo, hydroxy, C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C₆₋₁₂

halo substituted aryl up to per halo aryl, C₃-C₁₂ halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo heteraryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, and -C(O)R_g; or

-OSi(R_f)₃ where R_f is hydrogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₆₋₁₂ aryl, C₃-C₁₂ hetaryl having 1-3 heteroatoms selected from O, S and N, C₇₋₂₄ aralkyl, substituted C₁₋₁₀ alkyl, substituted C₁-C₁₀ alkoxy, substituted C₃-C₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, substituted C₃-C₁₂ heteraryl having 1-3 heteroatoms selected from O, S, and N, substituted C₆₋₁₂ aryl, and substituted C₇₋₂₄ alkaryl, where R_f is a substituted group it is substituted halogen up to per halo, hydroxy, C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C₆-C₁₂ halo substituted aryl up to per halo aryl, C₃-C₁₂ halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo heteraryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, and -C(O)R_g,

or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O with substituents selected from the group consisting of halogen up to per halo, hydroxy, C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, halo substituted C₁₋₆ alkyl up to per halo alkyl, halo substituted C₆-C₁₂ aryl up to per halo aryl, halo substituted C₃-C₁₂ cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo heteraryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, and -C(O)R_g,

or

c) one of R_a or R_b is -C(O)-, a C₁-C₅ divalent alkylene group or a substituted C₁-C₅ divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members,

wherein the substituents of the substituted C_1 - C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_7 - C_{24} alkaryl, C_7 - C_{24} aralkyl, C_{1-6} halo substituted alkyl up to per halo alkyl, C_{6-12} halo substituted aryl up to per halo aryl, C_{3-12} halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_{3-12} hetaryl up to per halo heteraryl, halo substituted C_7 - C_{24} aralkyl up to per halo aralkyl, halo substituted C_7 - C_{24} alkaryl up to per halo alkaryl, and $-C(O)R_g$,

where R_g is C_{1-10} alkyl; $-CN$, $-CO_2R_d$, $-OR_d$, $-SR_d$, $-NO_2$, $-C(O)R_e$, $-NR_dR_e$, $-NR_dC(O)OR_e$ and $-NR_dC(O)R_e$, and R_d and R_e are independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, C_{6-12} aryl, C_{3-12} hetaryl with 1-3 heteroatoms selected from O, N and S and C_7 - C_{24} aralkyl, C_7 - C_{24} alkaryl, up to per halo substituted C_1 - C_{10} alkyl, up to per halo substituted C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per halo substituted C_6 - C_{14} aryl, up to per halo substituted C_3 - C_{12} hetaryl having 1-3 heteroatoms selected from O, N, and S, halo substituted C_7 - C_{24} alkaryl up to per halo alkaryl, and up to per halo substituted C_7 - C_{24} aralkyl,

W is independently selected from the group consisting of $-CN$, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, C_2 - C_{10} alkenyl, C_1 - C_{10} alkenoyl, C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_6 - C_{14} aryl, C_7 - C_{24} alkaryl, C_7 - C_{24} aralkyl, C_{3-12} heteroaryl having 1-3 heteroatoms selected from O, N and S, C_4 - C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C_1 - C_{10} alkyl, substituted C_1 - C_{10} alkoxy, substituted C_2 - C_{10} alkenyl, substituted C_1 - C_{10} alkenoyl, substituted C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C_6 - C_{12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms selected from O, N and S, substituted C_7 - C_{24} aralkyl, substituted C_7 - C_{24} alkaryl, substituted C_4 - C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and $-Q$ -Ar;

R^7 is independently selected from H, C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, C_2 - C_{10} alkenyl, C_1 - C_{10} alkenoyl, C_3 - C_{10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_6 - C_{14} aryl, C_{3-13} hetaryl having 1-3 heteroatoms selected from O, N and S, C_7 - C_{14} alkaryl, C_7 - C_{24} aralkyl, C_4 - C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, up to per-

halosubstituted C₁-C₁₀ alkyl, up to per-halosubstituted C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per-halosubstituted C₆-C₁₄ aryl, up to per-halosubstituted C₃-C₁₃ hetaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C₇-C₂₄ aralkyl, up to per-halosubstituted C₇-C₂₄ alkaryl, and up to per-halosubstituted C₄-C₂₃ alkheteroaryl; and

each Z is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenyl, C₁-C₁₀ alkenoyl, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, C₆-C₁₄ aryl, C₃-C₁₃ hetaryl having 1-3 heteroatoms selected from O, N and S, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, C₄-C₂₃ alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C₁-C₁₀ alkyl, substituted C₁-C₁₀ alkoxy, substituted C₂-C₁₀ alkenyl, substituted C₁-C₁₀ alkenoyl, substituted C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C₆-C₁₂ aryl, substituted C₇-C₂₄ alkaryl, substituted C₇-C₂₄ aralkyl and substituted C₄-C₂₃ alkheteroaryl having 1-3 heteroatoms selected from O, N and S; wherein if Z is a substituted group, the one or more substituents are selected from the group consisting of -CN, -CO₂R⁷, -COR⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NO₂, -NR⁷R⁷, -NR⁷C(O)R⁷, and -NR⁷C(O)OR⁷.

3. (Previously Presented) A compound as in claim 1 wherein M is -O-.

4. (Currently Amended) A compound as in claim 1 wherein the cyclic structures of B and L bound directly to D have hydrogen substituents in the ortho position are ~~not substituted in the ortho position by -OH.~~

5. (Cancelled)

6. (Cancelled)

7. (Previously Presented) A compound of claim 1 wherein B of Formula I is an unsubstituted phenyl group.

8. **(Previously Presented)** A compound of claim 1 wherein B of Formula I is a substituted phenyl group, substituted 1 to 3 times by 1 or more substituents selected from the group consisting of -CN, halogen, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, -OH, up to per halo substituted C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkoxy or phenyl substituted by halogen up to per halo.

9. **(Cancelled)**

10. **(Previously presented)** A compound of claim 8, wherein L, the 6 member cyclic structure bound directly to D, is an unsubstituted phenyl group.

11. **(Cancelled)**

12. **(Previously Presented)** A compound of claim 1, wherein said substituted cyclic moiety L¹ is pyridinyl.

13. **(Previously Presented)** A compound of claim 3, wherein said substituted cyclic moiety L¹ is pyridinyl.

14. **(Previously Presented)** A compound of claim 7, wherein said substituted cyclic moiety L¹ is pyridinyl.

15. **(Previously Presented)** A compound of claim 8, wherein said substituted cyclic moiety L¹ is pyridinyl.

16. **(Cancelled)**

17. **(Previously Presented)** A compound of claim 10, wherein said substituted cyclic moiety L¹ is pyridinyl.

18. (Previously Presented) A compound of claim 14, wherein M is -O-.

19. (Previously Presented) A compound of claim 15, wherein M is -O-.

20. (Cancelled)

21. (Previously Presented) A compound of claim 17, wherein M is -O-.

22. (Original) A compound of claim 1 wherein L¹ is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo substituted C₁-C₁₀ alkoxy.

23. (Original) A compound of claim 13 wherein L¹ is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo substituted C₁-C₁₀ alkoxy.

24. (Original) A compound of claim 18 wherein L¹ is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo substituted C₁-C₁₀ alkoxy.

25. (Original) A compound of claim 19 wherein L¹ is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo substituted C₁-C₁₀ alkoxy.

26. (Cancelled)

27. **(Original)** A compound of claim 21 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C_1 - C_{10} alkyl, up to per halo substituted C_1 - C_{10} alkyl, -CN, -OH, halogen, C_1 - C_{10} alkoxy and up to per halo substituted C_1 - C_{10} alkoxy.

28. **(Cancelled)**

29. **(Cancelled)**

30. **(Original)** A compound of claim 1 wherein L^1 is substituted only by $-C(O)R_x$.

31. **(Cancelled)**

32. **(Cancelled)**

33. **(Previously Presented)** A compound of claim 13 wherein L^1 is substituted by $-C(O)R_x$ wherein R_x is NR_aR_b .

34. **(Previously Presented)** A compound of claim 18 wherein L^1 is substituted by $-C(O)R_x$ wherein R_x is NR_aR_b .

35. **(Previously Presented)** A compound of claim 19 wherein L^1 is substituted by $-C(O)R_x$, wherein R_x is NR_aR_b .

36. **(Cancelled)**

37. **(Previously Presented)** A compound of claim 21 wherein L^1 is substituted by $-C(O)R_x$ wherein R_x is NR_aR_b .

38. **(Previously Presented)** A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH- ,

A is a substituted moiety of up to 40 carbon atoms of the formula: $\text{-L-(M-L}^1\text{)}_q$, where L is a 6 membered aryl moiety which is unsubstituted phenyl bound directly to D, L^1 comprises a substituted cyclic moiety having at least 5 members which is phenyl or pyridinyl, M is -O- and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D which is phenyl or pyridinyl

wherein L^1 is substituted by -C(O)R_x

R_x is NR_aR_b where R_a and R_b are

a) independently hydrogen,

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O, which is of $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms selected from O, N and S, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from N, S and O, C_{7-24} aralkyl or $\text{C}_7\text{-C}_{24}$ alkaryl, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halo substituted alkyl up to per halo alkyl, $\text{C}_6\text{-C}_{12}$ halo substituted aryl up to per halo aryl, $\text{C}_3\text{-C}_{12}$ halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted $\text{C}_3\text{-C}_{12}$ hetaryl up to per halo hetaryl, halo substituted $\text{C}_7\text{-C}_{24}$ aralkyl up to per halo aralkyl, halo substituted $\text{C}_7\text{-C}_{24}$ alkaryl up to per halo alkaryl, or -C(O)R_g or

$\text{-OSi(R}_f\text{)}_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, $\text{C}_7\text{-C}_{24}$ alkaryl, $\text{C}_7\text{-C}_{24}$ aralkyl, C_{1-6} halo substituted alkyl up to per halo alkyl, $\text{C}_6\text{-C}_{12}$ halo substituted aryl up to per

halo aryl, C₃-C₁₂ halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo hetaryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, or -C(O)R_g, or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, halo substituted C₁₋₆ alkyl up to per halo alkyl, halo substituted C₆-C₁₂ aryl up to per halo aryl, halo substituted C₃-C₁₂ cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo hetaryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, or -C(O)R_g, or

c) one of R_a or R_b is -C(O)-, a C₁-C₅ divalent alkylene group or a substituted C₁-C₅ divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C₁-C₅ divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C₆-C₁₂ halo substituted aryl up to per halo aryl, C₃-C₁₂ halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo hetaryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, or -C(O)R_g, and are optionally substituted by halogen;

where B is substituted, L is substituted or L¹ is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W_n, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)NR⁷R⁷, -C(O)-R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, -Q-Ar, and

carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which are C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenyl, C₁-C₁₀ alkenoyl, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₆-C₁₄ aryl, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, or C₃-C₁₂ heteroaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NR⁷R⁷, -NO₂, -NR⁷C(O)R⁷, -NR⁷C(O)OR⁷ and halogen up to per-halo; with each R⁷ independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which are C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenyl, C₁-C₁₀ alkenoyl, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₆-C₁₄ aryl, C₃-C₁₃ hetaryl having 1-3 heteroatoms selected from O, N and S, C₇-C₁₄ alkaryl, C₇-C₂₄ aralkyl, C₄-C₂₃ alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by halogen,

wherein Q is -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-, where m= 1-3, and X^a is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which is C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenyl, C₁-C₁₀ alkenoyl, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, C₆-C₁₄ aryl, C₃-C₁₃ hetaryl having 1-3 heteroatoms selected from O, N and S, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, C₄-C₂₃ alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by one or more substituents are selected from the group consisting of -CN, -CO₂R⁷, -COR⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NO₂, -NR⁷R⁷, -NR⁷C(O)R⁷, and -NR⁷C(O)OR⁷, with R⁷ as defined above; and where R_g is C₁₋₁₀ alkyl; -CN, -CO₂R_d, -OR_d, -SR_d, -NO₂, -C(O)R_e, -NR_dR_e, -NR_dC(O)OR_e and -NR_dC(O)R_e, and R_d and R_e are independently selected from the group consisting of hydrogen, C₁₋₁₀, alkyl, C₁₋₁₀ alkoxy, C₃₋₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, C₆₋₁₂ aryl, C₃-C₁₂ hetaryl with 1-3 heteroatoms selected from O, N and S and C₇-C₂₄ aralkyl, C₇-

C₂₄ alkaryl, up to per halo substituted C₁-C₁₀ alkyl, up to per halo substituted C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per halo substituted C₆-C₁₄ aryl, up to per halo substituted C₃-C₁₂ hetaryl having 1-3 heteroatoms selected from O, N, and S, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, or up to per halo substituted C₇-C₂₄ aralkyl.

39. (Previously Presented) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L¹)_q, where L is a substituted or unsubstituted phenyl or pyridinyl moiety bound directly to D, L¹ comprises a substituted phenyl, or pyridinyl moiety, M is -O- and

B is a substituted or unsubstituted phenyl group bound directly to D,
wherein L¹ is substituted by-C(O)R_x,

R_x is NR_aR_b where R_a and R_b are

a) independently hydrogen,

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₃-₁₀ cycloalkyl, C₂-₁₀ alkenyl, C₁-₁₀ alkenoyl, C₆-₁₂ aryl, C₃-₁₂ hetaryl having 1-3 heteroatoms selected from O, N and S, C₃-₁₂ cycloalkyl having 0-3 heteroatoms selected from N, S and O, C₇-₂₄ aralkyl, or C₇-C₂₄ alkaryl, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁-₁₀ alkyl, C₃-₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃-₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁-₁₀ alkoxy, C₆-₁₂ aryl, C₁-₆ halo substituted alkyl up to per halo alkyl, C₆-C₁₂ halo substituted aryl up to per halo aryl, C₃-C₁₂ halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo hetaryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, or halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, and -C(O)R_g, or

-OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C₁-₁₀ alkyl, C₁-₁₀

alkoxy, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₆₋₁₂ aryl, or C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from O, S and N, C₇₋₂₄ aralkyl, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C_{7-C24} alkaryl, C_{7-C24} aralkyl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C_{6-C12} halo substituted aryl up to per halo aryl, C_{3-C12} halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_{3-C12} hetaryl up to per halo hetaryl, halo substituted C_{7-C24} aralkyl up to per halo aralkyl, or halo substituted C_{7-C24} alkaryl up to per halo alkaryl, and -C(O)R_g, or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, optionally substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C_{7-C24} alkaryl, C_{7-C24} aralkyl, halo substituted C₁₋₆ alkyl up to per halo alkyl, halo substituted C_{6-C12} aryl up to per halo aryl, halo substituted C_{3-C12} cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_{3-C12} hetaryl up to per halo hetaryl, halo substituted C_{7-C24} aralkyl up to per halo aralkyl, halo substituted C_{7-C24} alkaryl up to per halo alkaryl, or -C(O)R_g, or

c) one of R_a or R_b is -C(O)-, a C₁-C₅ divalent alkylene group or a substituted C₁-C₅ divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C₁-C₅ divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C_{7-C24} alkaryl, C_{7-C24} aralkyl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C_{6-C12} halo substituted aryl up to per halo aryl, C_{3-C12} halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_{3-C12} hetaryl up to per

halo hetaryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, or -C(O)R_g,

where B is substituted, L is substituted or L¹ is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W_n, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)NR⁷R⁷, -C(O)-R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which are C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenyl, C₁-C₁₀ alkenoyl, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₆-C₁₄ aryl, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, C₃-C₁₂ heteroaryl having 1-3 heteroatoms selected from O, N and S, or C₄-C₂₃ alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NR⁷R⁷, -NO₂, -NR⁷C(O)R⁷, -NR⁷C(O)OR⁷ and halogen up to per-halo; with each R⁷ independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which are C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenyl, C₁-C₁₀ alkenoyl, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₆-C₁₄ aryl, C₃-C₁₃ hetaryl having 1-3 heteroatoms selected from O, N and S, C₇-C₁₄ alkaryl, C₇-C₂₄ aralkyl, or C₄-C₂₃ alkheteroaryl having 1-3 heteroatoms selected from O, N and S,

wherein Q is -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-, CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-, where m= 1-3, and X^a is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which is C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenyl, C₁-C₁₀ alkenoyl, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, C₆-C₁₄ aryl, C₃-C₁₃ hetaryl having 1-3 heteroatoms selected from O, N and S, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, or C₄-C₂₃ alkheteroaryl having 1-3

heteroatoms selected from O, N and S, and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO₂R⁷, -COR⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NO₂, -NR⁷R⁷, -NR⁷C(O)R⁷, and -NR⁷C(O)OR⁷; and where R_g is C₁₋₁₀ alkyl; -CN, -CO₂R_d, -OR_d, -SR_d, -NO₂, -C(O)R_e, -NR_dR_e, -NR_dC(O)OR_e and -NR_dC(O)R_e, and R_d and R_e are independently selected from the group consisting of hydrogen, C₁₋₁₀, alkyl, C₁₋₁₀ alkoxy, C₃₋₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, C₆₋₁₂ aryl, C_{3-C12} hetaryl with 1-3 heteroatoms selected from O, N and S and C_{7-C24} aralkyl, C_{7-C24} alkaryl, up to per halo substituted C_{1-C10} alkyl, up to per halo substituted C_{3-C10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per halo substituted C_{6-C14} aryl, up to per halo substituted C_{3-C12} hetaryl having 1-3 heteroatoms selected from O, N, and S, halo substituted C_{7-C24} alkaryl up to per halo alkaryl, or up to per halo substituted C_{7-C24} aralkyl.

40. (Currently Amended) A compound as in claim 38 wherein the cyclic structures of B and L bound directly to D have hydrogen substituents in the ortho position are ~~not substituted in the ortho position by OH~~.

41. (Cancelled)

42. (Currently Amended) A compound as in claim 39 wherein the cyclic structures of B and L bound directly to D have hydrogen substituents in the ortho position are ~~not substituted in the ortho position by OH~~.

43. (Cancelled)

44. (Original) A compound as in claim 38 wherein substituents for B and L and additional substituents for L¹, are selected from the group consisting of C_{1-C10} alkyl up to per halo substituted C_{1-C10} alkyl, CN, OH, halogen, C_{1-C10} alkoxy and up to per halo substituted C_{1-C10} alkoxy.

45. (Original) A compound as in claim 39 wherein substituents for B and L and additional substituents for L¹, are selected from the group consisting of C_{1-C10} alkyl up to per

halo substituted C₁-C₁₀ alkyl, CN, OH, halogen, C₁-C₁₀ alkoxy and up to per halo substituted C₁-C₁₀ alkoxy.

46. (Cancelled)

47. (Cancelled)

48. (Previously Presented) A compound of claim 38 wherein R_a and R_b are independently hydrogen and C₁₋₆ alkyl.

49. (Previously Presented) A compound of claim 39 wherein ~~and~~ R_a and R_b are independently hydrogen and C₁₋₆ alkyl, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.

50. (Previously Presented) A pharmaceutically acceptable salt of a compound of formula I of claim 1 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

51. (Previously Presented) A pharmaceutically acceptable salt of a compound of claim 61 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

52. (Previously Presented) A pharmaceutically acceptable salt of a compound of claim 33 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

53. (Previously Presented) A pharmaceutically acceptable salt of a compound of claim 38 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

54. (Previously Presented) A pharmaceutically acceptable salt of a compound of claim 39 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

55. (Original) A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

56. (Previously Presented) A pharmaceutical composition comprising a compound of claim 2 and a physiologically acceptable carrier.

57. (Previously Presented) A pharmaceutical composition comprising a compound of claim 33 and a physiologically acceptable carrier.

58. (Previously Presented) A pharmaceutical composition comprising a compound of claim 38 and a physiologically acceptable carrier.

59. (Previously Presented) A pharmaceutical composition comprising a compound of claim 39 and a physiologically acceptable carrier.

60. (Cancelled)

61. (Currently Amended) A compound selected from the group consisting of
N-(3-*tert*-butylphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;
N-(3-*tert*-butylphenyl)-*N'*-(4-(4-acetylphenoxy)phenyl) urea;
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1,3-dioxoisindolin-5-yloxy)phenyl) urea[,];
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1-oxoisindolin-5-yloxy)phenyl) urea[,];
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea[,];
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea[,];
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea[,];
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea[,];
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea[,];
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea[,];
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea[,];
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea;
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea[,];
N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea[,];
N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea[,];

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea[.];

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea[.];

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea[.];

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea.

62. (Previously Presented) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of claim 1.

63. (Previously Presented) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of claim 33.

64. (Previously Presented) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of claim 38.

65. (Previously Presented) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of claim 39.

66. (Cancelled)

67. (Currently Amended) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound selected from the group consisting of

N-(3-*tert*-butylphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;
N-(3-*tert*-butylphenyl)-*N'*-(4-(4-acetylphenoxy)phenyl) urea;
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1,3-dioxoisindolin-5-yloxy)phenyl) urea[,] ;
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1-oxoisindolin-5-yloxy)phenyl) urea[,] ;
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea;
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea and
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;
N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;
N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea;

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea.


68. (Previously Presented) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of the formula:



wherein L is

phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₅ linear or branched alkyl, C₁-C₅ linear or branched haloalkyl up to perhalo, C₁-C₃ alkoxy, C₁-C₃ haloalkoxy up to per haloalkoxy, hydroxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino, halogen, cyano, and nitro;

L¹ comprises a substituted cyclic moiety which is

(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R^{7'}, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R^{7'}, NR⁷C(O)R^{7'}, NR⁷C(O)OR^{7'}, halogen, cyano and nitro;

(ii) pyridinyl optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R^{7'}, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R^{7'}, NR⁷C(O)R^{7'},

$\text{NR}^7\text{C(O)OR}^7$, halogen, cyano and nitro; C(O)OR^7 , $\text{C(O)NR}^7\text{R}^7$, $\text{NR}^7\text{C(O)R}^7$, $\text{NR}^7\text{C(O)OR}^7$, halogen, cyano and nitro; and

wherein L^1 is substituted by $-\text{C(O)R}_x$

wherein R_x is R_z or NR_aR_b and R_a and R_b are

a) independently R_z or $-\text{OSi}(\text{R}_f)_3$; or

b) combined together to form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, optionally substituted by halogen, hydroxy or

R_y , or

c) one of R_a or R_b is $-\text{C(O)-}$, a C_1 - C_5 divalent alkylene group or a substituted

C_1 - C_5 divalent alkylene group bound to the moiety L^1 to form a cyclic structure with at least 5 members, wherein the substituents of the substituted

C_1 - C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and R_y ;

M is $-\text{O}-$

B is

(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R^7 , OR^7 , NR^7R^7 , C(O)R^7 , C(O)OR^7 , $\text{C(O)NR}^7\text{R}^7$, $\text{NR}^7\text{C(O)R}^7$, $\text{NR}^7\text{C(O)OR}^7$ halogen, cyano, and nitro; or

(ii) pyridinyl optionally substituted with 1-3 substituents independently selected from the group consisting of R^7 , OR^7 , NR^7R^7 , C(O)R^7 , C(O)OR^7 , $\text{C(O)NR}^7\text{R}^7$, $\text{NR}^7\text{C(O)R}^7$, $\text{NR}^7\text{C(O)OR}^7$, halogen, cyano, and nitro; and

each R^7 , R^7 , R_z and R_f is independently

(a) hydrogen,

(b) C_1 - C_6 linear, branched, or cyclic alkyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_5 linear or branched alkyl, up to perhalo substituted C_1 - C_5 linear or branched alkyl, C_1 - C_3 alkoxy and hydroxy;

(c) C_1 - C_6 alkoxy, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_5 linear or branched alkyl, up to perhalo substituted C_1 - C_5 linear or branched alkyl, C_1 - C_3 alkoxy, hydroxy and halogen;

(d) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_5 linear or branched alkyl, up to perhalo substituted C_1 - C_5 linear or branched alkyl, C_1 - C_3 alkoxy, hydroxy and halogen,

(e) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₅ linear or branched alkyl, up to perhalo substituted C₁-C₅ linear or branched alkyl, C₁-C₃ alkoxy, hydroxy and halogen,

(f) C₁-C₃ alkyl-phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₅ linear or branched alkyl, up to perhalo substituted C₁-C₅ linear or branched alkyl, C₁-C₃ alkoxy, hydroxy and halogen; and

(g) up to per-halo substituted C₁-C₅ linear, branched or cyclic alkyl, and where not per-halo substituted, optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₅ linear or branched alkyl, up to perhalo substituted C₁-C₅ linear or branched alkyl, C₁-C₃ alkoxy and hydroxy.

69. (Cancelled)

70. (Cancelled)

71. (Cancelled)

72. (Cancelled)

73. (Previously Presented) A compound of claim 68 wherein the substituents of the substituted structures of L are selected from the group consisting of methyl, trifluoromethyl, ethyl, n-propyl, n-butyl, n-pentyl, i-propyl, t-butyl, methoxy, ethoxy, propoxy, Cl, Br, F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino, ethylamino and diethylamino.

74. (Previously Presented) A compound of claim 68 wherein the substituents of the substituted structures of B and L¹ are independently selected from the group consisting of methyl, trifluoromethyl, ethyl, n-propyl, n-butyl, n-pentyl, isopropyl, *tert*-butyl, *sec*-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, propoxy, Cl, Br and F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino, ethylamino and diethylamino.

75. (Cancelled)

76. **(Previously Presented)** A compound as in claim 68 wherein B, L and L¹ follow one of the following of combinations:

- B= phenyl, L=phenyl and L¹ is phenyl,
- B= phenyl, L=phenyl and L¹ is pyridinyl,
- B=pyridinyl, L= phenyl and L¹ is phenyl,
- B=pyridinyl, L=phenyl and L¹ is pyridinyl,

77. **(Previously Presented)** A pharmaceutical composition for the treatment of a cancerous cell growth comprising a compound of claim 68 or a pharmaceutically acceptable salt of a compound of formula I and a physiologically acceptable carrier.

78. **(Cancelled)**

79. **(Cancelled)**

80. **(Previously Presented)** A pharmaceutical composition for the treatment of a cancerous cell growth as in claim 77 wherein the pharmaceutically acceptable salt is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

81. **(Cancelled)**

82. **(Cancelled)**

83. **(Currently Amended)** A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is $-\text{NH}-\text{C}(\text{O})-\text{NH}-$,

A is a substituted moiety of up to 40 carbon atoms of the formula: $-\text{L}-(\text{M}-\text{L}^1)_q$, where L is a 6 membered cyclic structure, which is substituted phenyl or unsubstituted phenyl, bound directly to D, L^1 comprises a substituted cyclic moiety having at least 5 members which is phenyl or pyridinyl,

M is one or more bridging groups selected from the group consisting of $-\text{O}-$, $-\text{S}-$, $-\text{NR}^7-$, $-\text{N}(\text{R}^7)-$ where R^7 is hydrogen, q is an integer of from 1-3; and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D which is phenyl or pyridinyl,

wherein L^1 is substituted by $-\text{S}(\text{O})_2\text{R}_x$,

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 heteroatom, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_3-C_{12} hetaryl having 1-3 heteroatoms selected from, S, N and O, C_{7-24} alkaryl, C_{7-24} aralkyl, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halo substituted alkyl up to per halo alkyl, C_6-C_{12} halo substituted aryl up to per halo aryl, C_3-C_{12} halo substituted cycloalkyl up to per halo cycloalkyl having 0-3 heteroatoms selected from N, S and O, halo substituted C_3-C_{12} hetaryl up to per halo hetaryl having 1-3 heteroatoms selected from O, N and S, halo substituted C_7-C_{24} aralkyl up to per halo aralkyl, halo substituted C_7-C_{24} alkaryl up to per halo alkaryl, or $-\text{C}(\text{O})\text{R}_g$;

R_x is R_z or NR_aR_b where R_a and R_b are

a) independently hydrogen,

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms selected from O, N and S, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from N, S and O, C_{7-24} aralkyl, or C_7-C_{24} alkaryl, and is optionally substituted by halogen, hydroxy and carbon

based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C_{6-C12} halo substituted aryl up to per halo aryl, C_{3-C12} halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_{3-C12} hetaryl up to per halo hetaryl, halo substituted C_{7-C24} aralkyl up to per halo aralkyl, halo substituted C_{7-C24} alkaryl up to per halo alkaryl, or -C(O)R_g and are optionally substituted by halogen, or

-OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C_{3-C10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₆₋₁₂ aryl, C_{3-C12} hetaryl having 1-3 heteroatoms selected from O, S and N, or C₇₋₂₄ aralkyl, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C_{7-C24} alkaryl, C_{7-C24} aralkyl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C_{6-C12} halo substituted aryl up to per halo aryl, C_{3-C12} halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_{3-C12} hetaryl up to per halo hetaryl, halo substituted C_{7-C24} aralkyl up to per halo aralkyl, halo substituted C_{7-C24} alkaryl up to per halo alkaryl, or -C(O)R_g, or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, optionally substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C_{7-C24} alkaryl, C_{7-C24} aralkyl, halo substituted C₁₋₆ alkyl up to per halo alkyl, halo substituted C_{6-C12} aryl up to per halo aryl, halo substituted C_{3-C12} cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_{3-C12} hetaryl up to per halo hetaryl, halo substituted C_{7-C24} aralkyl up to per halo aralkyl, halo substituted C_{7-C24} alkaryl up to per halo alkaryl, or -C(O)R_g, or

c) one of R_a or R_b is $-C(O)-$, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_7-C_{24} alkaryl, C_7-C_{24} aralkyl, C_{1-6} halo substituted alkyl up to per halo alkyl, C_6-C_{12} halo substituted aryl up to per halo aryl, C_3-C_{12} halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_3-C_{12} hetaryl up to per halo hetaryl, halo substituted C_7-C_{24} aralkyl up to per halo aralkyl, halo substituted C_7-C_{24} alkaryl up to per halo alkaryl, or $-C(O)R_g$,

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W_n , where n is 0-3;

wherein each W is independently selected from the group consisting of $-CN$, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, $-Q-Ar$, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which are C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_6-C_{14} aryl, C_7-C_{24} alkaryl, C_7-C_{24} aralkyl, C_3-C_{12} heteroaryl having 1-3 heteroatoms selected from O, N and S, or C_4-C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by one or more substituents independently selected from the group consisting of $-CN$, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ and halogen up to per-halo; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which are C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_6-C_{14} aryl, C_3-C_{13} hetaryl having 1-3 heteroatoms selected from O, N and S, C_7-C_{14} alkaryl, C_7-C_{24} aralkyl, or C_4-C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by halogen,

wherein Q is -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-, where m= 1-3, and X^a is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which is C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenyl, C₁-C₁₀ alkenoyl, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, C₆-C₁₄ aryl, or C₃-C₁₃ hetaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO₂R⁷, -COR⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NO₂, -NR⁷R⁷, -NR⁷C(O)R⁷, and -NR⁷C(O)OR⁷, with R⁷ as defined above,

where R_g is C₁₋₁₀ alkyl; -CN, -CO₂R_d, -OR_d, -SR_d, -NO₂, -C(O)R_e, -NR_dR_e, -NR_dC(O)OR_e and -NR_dC(O)R_e, and R_d and R_e are independently selected from the group consisting of hydrogen, C₁₋₁₀, alkyl, C₁₋₁₀ alkoxy, C₃₋₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, C₆₋₁₂ aryl, C₃-C₁₂ hetaryl with 1-3 heteroatoms selected from O, N and S and C₇-C₂₄ aralkyl, C₇-C₂₄ alkaryl, up to per halo substituted C₁-C₁₀ alkyl, up to per halo substituted C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per halo substituted C₆-C₁₄ aryl, up to per halo substituted C₃-C₁₂ hetaryl having 1-3 heteroatoms selected from O, N, and S, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, and up to per halo substituted C₇-C₂₄ aralkyl.

84. (Currently Amended) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L¹)_q, where L is a 6 membered cyclic structure, which is substituted phenyl or unsubstituted

phenyl, bound directly to D, L^1 comprises a substituted cyclic moiety having at least 5 members which is phenyl or pyridinyl,

M is one or more bridging groups selected from the group consisting of -O-, -S-, and $-NR^7-$ $-N(R^7)-$ wherein R^7 is hydrogen, q is an integer of from 1-3; and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D which is phenyl or pyridinyl,

wherein L^1 is substituted by $-C(NR_y)R_z$,

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 heteroatom, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_3-C_{12} hetaryl having 1-3 heteroatoms selected from, S, N and O, C_{7-24} alkaryl, C_{7-24} or aralkyl, and optionally substituted by halogen or hydroxy;

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 heteroatom, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_3-C_{12} hetaryl having 1-3 heteroatoms selected from, S, N and O, C_{7-24} alkaryl, C_{7-24} or aralkyl, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halo substituted alkyl up to per halo alkyl, $C_{6-C_{12}}$ halo substituted aryl up to per halo aryl, C_3-C_{12} halo substituted cycloalkyl up to per halo cycloalkyl having 0-3 heteroatoms selected from N, S and O, halo substituted C_3-C_{12} hetaryl up to per halo hetaryl having 1-3 heteroatoms selected from O, N and S, halo substituted C_7-C_{24} aralkyl up to per halo aralkyl, halo substituted C_7-C_{24} alkaryl up to per halo alkaryl, or $-C(O)R_g$;

R_x is R_z or NR_aR_b where R_a and R_b are

a) independently hydrogen,

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms selected from O, N and S, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from N, S and O,

C₇₋₂₄ aralkyl, or C₇-C₂₄ alkaryl, and is optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C₆-C₁₂ halo substituted aryl up to per halo aryl, C₃-C₁₂ halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo hetaryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, or -C(O)R_g and are optionally substituted by halogen, or

-OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O, which is C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₆₋₁₂ aryl, C₃-C₁₂ hetaryl having 1-3 heteroatoms selected from O, S and N, or C₇₋₂₄ aralkyl, and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, C₁₋₆ halo substituted alkyl up to per halo alkyl, C₆-C₁₂ halo substituted aryl up to per halo aryl, C₃-C₁₂ halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo hetaryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, or -C(O)R_g, or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, optionally substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C₁₋₁₀ alkyl, C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N, C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O, C₁₋₁₀ alkoxy, C₆₋₁₂ aryl, C₇-C₂₄ alkaryl, C₇-C₂₄ aralkyl, halo substituted C₁₋₆ alkyl up to per halo alkyl, halo substituted C₆-C₁₂ aryl up to per halo aryl, halo substituted C₃-C₁₂ cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C₃-C₁₂ hetaryl up to per halo hetaryl, halo substituted C₇-C₂₄ aralkyl up to per halo aralkyl, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, or -C(O)R_g, or

c) one of R_a or R_b is $-C(O)-$, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O, which are C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_7-C_{24} alkaryl, C_7-C_{24} aralkyl, C_{1-6} halo substituted alkyl up to per halo alkyl, C_6-C_{12} halo substituted aryl up to per halo aryl, C_3-C_{12} halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_3-C_{12} hetaryl up to per halo hetaryl, halo substituted C_7-C_{24} aralkyl up to per halo aralkyl, halo substituted C_7-C_{24} alkaryl up to per halo alkaryl, or $-C(O)R_g$,

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W_n , where n is 0-3;

wherein each W is independently selected from the group consisting of $-CN$, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, $-Q-Ar$, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which are C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_6-C_{14} aryl, C_7-C_{24} alkaryl, C_7-C_{24} aralkyl, C_3-C_{12} heteroaryl having 1-3 heteroatoms selected from O, N and S, or C_4-C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by one or more substituents independently selected from the group consisting of $-CN$, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ and halogen up to per-halo; with each R^7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which are C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_6-C_{14} aryl, C_3-C_{13} hetaryl having 1-3 heteroatoms selected from O, N and S, C_7-C_{14} alkaryl, C_7-C_{24} aralkyl, or C_4-C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by halogen,

wherein Q is -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-, where m= 1-3, and X^a is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O, which is C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenyl, C₁-C₁₀ alkenoyl, C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, C₆-C₁₄ aryl, or C₃-C₁₃ hetaryl having 1-3 heteroatoms selected from O, N and S, and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO₂R⁷, -COR⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NO₂, -NR⁷R⁷, -NR⁷C(O)R⁷, and -NR⁷C(O)OR⁷, with R⁷ as defined above,

where R_g is C₁₋₁₀ alkyl; -CN, -CO₂R_d, -OR_d, -SR_d, -NO₂, -C(O)R_e, -NR_dR_e, -NR_dC(O)OR_e and -NR_dC(O)R_e, and R_d and R_e are independently selected from the group consisting of hydrogen, C₁₋₁₀, alkyl, C₁₋₁₀ alkoxy, C₃₋₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, C₆₋₁₂ aryl, C₃-C₁₂ hetaryl with 1-3 heteroatoms selected from O, N and S and C₇-C₂₄ aralkyl, C₇-C₂₄ alkaryl, up to per halo substituted C₁-C₁₀ alkyl, up to per halo substituted C₃-C₁₀ cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per halo substituted C₆-C₁₄ aryl, up to per halo substituted C₃-C₁₂ hetaryl having 1-3 heteroatoms selected from O, N, and S, halo substituted C₇-C₂₄ alkaryl up to per halo alkaryl, and up to per halo substituted C₇-C₂₄ aralkyl.

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A method for treating a disease in a human or other mammal mediated by a VEGF-induced signal transduction pathway, wherein the disease that is treated is one or more of the following conditions: retinopathy and retinopathy of prematurity, comprising administering to a human or other mammal in need thereof a compound of Formula I, a salt form of a compound of Formula I, an isomer of a compound of Formula I or a prodrug of a compound of Formula I to regulate a VEGF-mediated signal transduction cascade,



wherein A is selected from the group consisting of

(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro;

(iii) 6 membered monocyclic heteroaryl groups, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro; and

(iv) 10 membered bicyclic heteroaryl groups in which the first ring is bonded to the NH of Figure I and contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S, and the second ring is fused to the first ring using 3 to 4 carbon atoms, the bicyclic heteroaryl group is optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro,

B is selected from the group consisting of

(i) phenyl, substituted with 1-2 substituents independently selected from the group consisting of -L-M, optionally substituted with C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched haloalkyl, C_1 - C_3 alkoxy, hydroxy, amino, C_1 - C_3 alkylamino, C_1 - C_6 dialkylamino, halogen, cyano, and nitro;

(ii) naphthyl, substituted with 1-2 substituents independently selected from the group consisting of -L-M, optionally substituted with C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched haloalkyl, C_1 - C_3 alkoxy, hydroxy, amino, C_1 - C_3 alkylamino, C_1 - C_6 dialkylamino, halogen, cyano, and nitro;

(iii) 6 membered monocyclic heteroaryl groups, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, substituted with 1-2 substituents independently selected from the group consisting of -L-M, optionally substituted with C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched haloalkyl, C_1 - C_3 alkoxy, hydroxy, amino, C_1 - C_3 alkylamino, C_1 - C_6 dialkylamino, halogen, cyano, and nitro;

(iv) 10 membered bicyclic heteroaryl groups having 1-6 heteroatoms independently selected from the group consisting of O, N and S, substituted with 1-2 substituents independently selected from the group consisting of -L-M, optionally substituted

with C₁-C₅ linear or branched alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₃ alkoxy, hydroxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino, halogen, cyano, and nitro;

L is selected from the group consisting of:

- (a) $-(CH_2)_m-O-(CH_2)_l-$,
- (b) $-(CH_2)_m-(CH_2)_l-$,
- (c) $-(CH_2)_m-C(O)-(CH_2)_l-$,
- (d) $-(CH_2)_m-NR^3-(CH_2)_l-$,
- (e) $-(CH_2)_m-NR^3C(O)-(CH_2)_l-$,
- (f) $-(CH_2)_m-S-(CH_2)_l-$,
- (g) $-(CH_2)_m-C(O)NR^3-(CH_2)_l-$,
- (h) $-(CH_2)_m-CF_2-(CH_2)_l-$,
- (i) $-(CH_2)_m-CCl_2-(CH_2)_l-$,
- (j) $-(CH_2)_m-CHF-(CH_2)_l-$,
- (k) $-(CH_2)_m-CH(OH)-(CH_2)_l-$;
- (l) $-(CH_2)_m-C\equiv C-(CH_2)_l-$;
- (m) $-(CH_2)_m-C\equiv C-(CH_2)_l-$ $-(CH_2)_m-CH=CH-(CH_2)_l-$; and
- (n) $-(CH_2)_m-CR^4R^5-(CH_2)_l-$;

wherein the variables m and l are integers independently selected from 0-4,

M is selected from the group consisting of:

- (i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R¹, OR¹, NR¹R², S(O)_qR¹, SO₂NR¹R², NR¹SO₂R², C(O)R¹, C(O)OR¹, C(O)NR¹R², NR¹C(O)R², NR¹C(O)OR², halogen, cyano and nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano and nitro;

(iii) 6 membered monocyclic heteroaryl groups, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro and also oxides (e.g. $=O$, O^- or OH); and

(iv) 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro and also oxides (e.g. $=O$, O^- or OH);

(v) saturated and partially saturated C_3 - C_6 monocyclic carbocyclic moiety optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano and $[[,]]$ nitro;

(vi) saturated and partially saturated C_8 - C_{10} bicyclic carbocyclic moiety, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano and nitro;

(vii) saturated and partially saturated 5 and 6 membered monocyclic heterocyclic moiety, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group

consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro, and also oxides (e.g. $=O$, $-O^-$ or $-OH$); and

(viii) saturated and partially saturated 8 to 10 membered bicyclic heterocyclic moiety, having 1-6 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro, and also oxides (e.g. $=O$, $-O^-$ or $-OH$);

wherein each $R^1 - R^5$ is independently selected from the group consisting of:

- (a) hydrogen,
- (b) C_1 - C_6 alkyl, preferably, ~~C_1 - C_5 -linear, branched, or cyclic alkyl~~, wherein said alkyl is optionally substituted with halogen up to per-halo;
- (c) phenyl;
- (d) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms selected from the group consisting of O, N and S;
- (e) C_1 - C_3 alkyl-phenyl wherein said alkyl moiety is optionally substituted with halogen up to per-halo; and
- (f) C_1 - C_3 alkyl-heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S, wherein said heteroaryl group is a 5-6 membered monocyclic heteroaryl or a 8-10 membered bicyclic heteroaryl, and wherein said alkyl moiety is optionally substituted with halogen up to per-halo,

wherein each $R^1 - R^5$, when not hydrogen is optionally substituted with 1-3 substituents independently selected from the group consisting of C_1-C_5 linear branched or cyclic alkyl, wherein said alkyl is optionally substituted with halogen up to per-halo, C_1-C_3 alkoxy, wherein said alkoxy is optionally substituted with halogen up to per-halo, hydroxy, amino, C_1-C_3 alkylamino, C_2-C_6 dialkylamino, halogen, cyano, and nitro;

each variable q is independently selected from 0, 1, or 2; and

wherein A, B and M of formula I follow one of the following combinations:

A= phenyl, B=phenyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,

A= phenyl, B=pyridinyl and M is pyridinyl, quinolinyl, isoquinolinyl or not present,

A=phenyl, B = naphthyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,

A=pyridinyl, B= phenyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,

A=pyridinyl, B= pyridinyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,

A=pyridinyl, B= naphthyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,

A=isoquinolinyl, B= phenyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,

A= isoquinolinyl, B= pyridinyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,

A= isoquinolinyl, B= naphthyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,

A= quinoliny, B= phenyl and M is phenyl, pyridiny, quinoliny, isoquinoliny or not present,

A= quinoliny, B= pyridiny and M is phenyl, pyridiny, quinoliny, isoquinoliny or not present, or

A= quinoliny, B= naphthyl and M is phenyl, pyridiny, quinoliny, isoquinoliny or not present.

2. (Canceled)

3. (Currently Amended) A method as in claim 1 wherein the substituents on the groups for A, B, and M are selected from the group consisting of: methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, *sec*-butyl, [[and]] *tert*-butyl, F, Cl, Br, and I.

4.—5. (Canceled)

6. (Currently Amended) A method of claim 1 wherein the substituents of the substituted structures of B are each, independently, selected from the group consisting of methyl, trifluoromethyl, ethyl, n-propyl, n-butyl, n-pentyl, isopropyl, isobutyl, *sec*-butyl, *tert*-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, propoxy, Cl, Br, [[and]] F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino, ethylamino, diethylamino and the structure -L-M.

7. (Currently Amended) A method of claim 6 wherein the substituents of the substituted structures of A and M are each, independently, selected from the group consisting of

methyl, trifluoromethyl, ethyl, n-propyl, n-butyl, n-pentyl, isopropyl, *tert*-butyl, sec-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, propoxy, Cl, Br, [[and]] F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino, ethylamino and diethylamino and further include:

phenyl, pyridinyl, pyrimidinyl, chlorophenyl, dichlorophenyl, bromophenyl, dibromophenyl, chloropyridinyl, bromopyridinyl, dichloropyridinyl, dibromopyridinyl, methylphenyl, methylpyridinyl, quinolinyl, isoquinolinyl, isoindolinyl, pyrazinyl, pyridazinyl, pyrrolinyl, imidazolynyl, thienyl, furyl, isoxazolynyl, isothiazolynyl, benzopyridinyl, benzothiazolyl, C₁-C₅ acyl;

NH(C₁-C₅ alkyl, phenyl or pyridinyl); ~~such as aminophenyl;~~

N(C₁-C₅ alkyl)(C₁-C₅ alkyl, phenyl or pyridinyl); ~~such as diethylamino and dimethyl amino;~~

S(O)_q (C₁-C₅ alkyl); ~~such as methanesulfonyl;~~

S(O)_q H;

SO₂NH₂;

SO₂NH(C₁-C₅ alkyl);

SO₂N(C₁-C₅ alkyl)(C₁-C₅ alkyl);

NHSO₂(C₁-C₅ alkyl); N(C₁-C₃ alkyl) SO₂(C₁-C₅ alkyl);

CO(C₁-C₆ alkyl or phenyl);

C(O)H;

C(O)O(C₁-C₆ alkyl or phenyl); ~~such as C(O)OCH₃, C(O)OCH₂CH₃,
C(O)OCH₂CH₂CH₃;~~

C(O)OH;

C(O)NH₂ (carbamoyl);

~~C(O)NH(C₁-C₆ alkyl or phenyl), such as N-methylethyl carbamoyl, N-methyl carbamoyl, N-ethylcarbamoyl, or N-dimethylamino-ethyl-carbamoyl;~~

~~C(O)N(C₁-C₆ alkyl or phenyl)(C₁-C₆ alkyl, phenyl or pyridinyl), such as N-dimethyl carbamoyl;~~

C(N(C₁-C₅ alkyl))(C₁-C₅ alkyl);

NHC(O)(C₁-C₆ alkyl or phenyl) and

N(C₁-C₅ alkyl)[[,]]C(O)(C₁-C₅ alkyl).

wherein each of the above substituents is optionally partially or fully halogenated.

8. **(Previously Presented)** A method as in claim 1 wherein A and M of formula I are independently selected from the group consisting of substituted or unsubstituted phenyl and pyridinyl.

9. **(Previously Presented)** A method as in claim 8 wherein B of formula I is a phenyl group, optionally substituted by halogen up to per halo and 0 to 3 times by one or more substituents selected from the group consisting of -CN, C₁-C₅ alkyl, C₁-C₅ alkoxy, -OH, phenyl, up to per halo substituted C₁-C₅ alkyl, up to per halo substituted C₁-C₅ alkoxy and up to per halo substituted phenyl.

10. **(Canceled)**

11. **(Currently Amended)** A method as in claim 1 wherein L of formula I is -O-, -S-, -NH-, -N(CH₃)-, -NHCH₂-, -NC₂H₄-, -CH₂-, -C(O)-, -CH(OH)-, -NHC(O)N(CH₃)CH₂-, -N(CH₃)C(O)N(CH₃)CH₂-, -CH₂C(O)N(CH₃)-, -C(O)N(CH₃)CH₂-,

-NHC(O)-, -N(CH₃)C(O)-, -C(O)N(CH₃)-, -C(O)NH-, -CH₂O-, -CH₂S-, -CH₂N(CH₃)-, -OCH₂-, -CHF-, -CF₂-, -CCl₂-, -S-CH₂-, or and -N(CH₃)CH₂-.

12.—17. (Canceled)

18. (Currently Amended) A method for treating a disease in a human or other mammal mediated by a VEGF-induced signal transduction pathway, wherein the disease that is treated is one or more of the following conditions: retinopathy and retinopathy of prematurity, comprising administering to a human or other mammal in need thereof a compound of Formula I, a salt form of a compound of Formula I, an isomer of a compound of Formula I or a prodrug of a compound of Formula I to regulate a VEGF-mediated signal transduction cascade,



wherein A is selected from the group consisting of

(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R¹, OR¹, NR¹R², S(O)_qR¹, SO₂NR¹R², NR¹SO₂R², C(O)R¹, C(O)OR¹, C(O)NR¹R², NR¹C(O)R², NR¹C(O)OR², halogen, cyano, and nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R¹, OR¹, NR¹R², S(O)_qR¹, SO₂NR¹R², NR¹SO₂R², C(O)R¹, C(O)OR¹, C(O)NR¹R², NR¹C(O)R², NR¹C(O)OR², halogen, cyano, and nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R¹, OR¹, NR¹R², S(O)_qR¹, SO₂NR¹R², NR¹SO₂R², C(O)R¹, C(O)OR¹, C(O)NR¹R², NR¹C(O)R², NR¹C(O)OR², halogen, cyano, and nitro; and

(iv) 8 to 10 membered bicyclic heteroaryl groups in which the first ring is bonded to the NH of Figure I and contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S, and the second ring is fused to the first ring using 3 to 4 carbon atoms, the bicyclic heteroaryl group is optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro,

B is selected from the group consisting of

(i) phenyl, substituted with 1-3 substituents independently selected from the group consisting of -L-M, C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched haloalkyl, C_1 - C_3 alkoxy, hydroxy, amino, C_1 - C_3 alkylamino, C_1 - C_6 dialkylamino, halogen, cyano, and nitro;

(ii) naphthyl, substituted with 1-3 substituents independently selected from the group consisting of -L-M, C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched haloalkyl, C_1 - C_3 alkoxy, hydroxy, amino, C_1 - C_3 alkylamino, C_1 - C_6 dialkylamino, halogen, cyano, and nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, substituted with 1-3 substituents independently selected from the group consisting of -L-M, C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched haloalkyl, C_1 - C_3 alkoxy, hydroxy, amino, C_1 - C_3 alkylamino, C_1 - C_6 dialkylamino, halogen, cyano, and nitro; and

(iv) 8 to 10 membered bicyclic heteroaryl groups having 1-6 heteroatoms independently selected from the group consisting of O, N and S, substituted with 1-3 substituents independently selected from the group consisting of -L-M, C_1 - C_5 linear or

branched alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₃ alkoxy, hydroxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino, halogen, cyano, and nitro;

L is selected from the group consisting of:

- (a) $-(CH_2)_m-O-(CH_2)_l-$,
- (b) $-(CH_2)_m-(CH_2)_l-$,
- (c) $-(CH_2)_m-C(O)-(CH_2)_l-$,
- (d) $-(CH_2)_m-NR^3-(CH_2)_l-$,
- (e) $-(CH_2)_m-NR^3C(O)-(CH_2)_l-$,
- (f) $-(CH_2)_m-S-(CH_2)_l-$,
- (g) $-(CH_2)_m-C(O)NR^3-(CH_2)_l-$,
- (h) $-(CH_2)_m-CF_2-(CH_2)_l-$,
- (i) $-(CH_2)_m-CCl_2-(CH_2)_l-$,
- (j) $-(CH_2)_m-CHF-(CH_2)_l-$,
- (k) $-(CH_2)_m-CH(OH)-(CH_2)_l-$;
- (l) $-(CH_2)_m-C\equiv C-(CH_2)_l-$;
- (m) $-(CH_2)_m-C\equiv C-(CH_2)_l-$ $-(CH_2)_m-CH=CH-(CH_2)_l-$; and
- (n) $-(CH_2)_m-CR^4R^5-(CH_2)_l-$;

wherein the variables m and l are integers independently selected from 0-4,

M is selected from the group consisting of:

- (i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R¹, OR¹, NR¹R², S(O)_qR¹, SO₂NR¹R², NR¹SO₂R², C(O)R¹, C(O)OR¹, C(O)NR¹R², NR¹C(O)R², NR¹C(O)OR², halogen, cyano and nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano and nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro and also oxides (e.g. $=O$, $-O^-$ or $-OH$); and

(iv) 8 to 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro and also oxides (e.g. $=O$, $-O^-$ or $-OH$);

(v) saturated and partially saturated C_3 - C_6 monocyclic carbocyclic moiety optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano and $[[.]]$ nitro;

(vi) saturated and partially saturated C_8 - C_{10} bicyclic carbocyclic moiety, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano and nitro;

(vii) saturated and partially saturated 5 and 6 membered monocyclic heterocyclic moiety, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group

consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro, and also oxides (e.g., $=O$, $-O^-$ or $-OH$); and

(viii) saturated and partially saturated 8 to 10 membered bicyclic heterocyclic moiety, having 1-6 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro, and also oxides (e.g., $=O$, $-O^-$ or $-OH$);

wherein each $R^1 - R^5$ is independently selected from the group consisting of:

- (a) hydrogen,
- (b) C_1 - C_6 alkyl, preferably, ~~C_1 - C_5 linear, branched, or cyclic alkyl~~, wherein said alkyl is optionally substituted with halogen up to per-halo;
- (c) phenyl;
- (d) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms selected from the group consisting of O, N and S;
- (e) C_1 - C_3 alkyl-phenyl wherein said alkyl moiety is optionally substituted with halogen up to per-halo; and
- (f) C_1 - C_3 alkyl-heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S, wherein said heteroaryl group is a 5-6 membered monocyclic heteroaryl or a 8-10 membered bicyclic heteroaryl, and wherein said alkyl moiety is optionally substituted with halogen up to per-halo,

wherein each $R^1 - R^5$, when not hydrogen is optionally substituted with 1-3 substituents independently selected from the group consisting of C_1-C_5 linear branched or cyclic alkyl, wherein said alkyl is optionally substituted with halogen up to per-halo, C_1-C_3 alkoxy, wherein said alkoxy is optionally substituted with halogen up to per-halo, hydroxy, amino, C_1-C_3 alkylamino, C_2-C_6 dialkylamino, halogen, cyano, and nitro;

each variable q is independently selected from 0, 1, or 2;


wherein B is substituted by $-L-M$ and

M is substituted by at least one substituent selected from the group consisting of $S(O)_qR^1$, $SO_2NR^1R^2$, $C(O)R^1$, $C(O)OR^1$ and $C(O)NR^1R^2$.

19. (Previously Presented) A method as in claim 18, wherein M is substituted by at least one substituent selected from the group consisting of $-C(O)R^1$, $C(O)OR^1$, and $C(O)NR^1R^2$, wherein R^1 and R^2 are independently as defined in claim 18.

20. (Previously Presented) A method of claim 18 wherein M is substituted by $-C(O)NR^1R^2$, wherein R^1 and R^2 are independently as defined in claim 18.

21. (Previously Presented) A method for treating a disease in a human or other mammal mediated by a VEGF-induced signal transduction pathway wherein the disease that is treated is one or more of the following conditions: retinopathy and retinopathy of prematurity, comprising administering to a human or other mammal in need thereof the compound $N-(4\text{-chloro-3-(trifluoromethyl)phenyl})-N'-(4\text{-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl})$ urea of the formula below or a pharmaceutically acceptable salt thereof to regulate a VEGF-mediated signal transduction cascade,



22. (Previously Presented) A method for treating a disease in a human or other mammal mediated by a VEGF-induced signal transduction pathway wherein the disease that is treated is one or more of the following conditions: retinopathy and retinopathy of prematurity, comprising administering to a human or other mammal in need thereof the compound N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea tosylate to regulate a VEGF-mediated signal transduction cascade.

23. (Previously Presented) A method of claim 18 wherein the structures of A, B and M are each, independently selected from the group consisting of phenyl, substituted phenyl, pyridinyl, substituted pyridinyl, pyrimidinyl, substituted pyrimidinyl, naphthyl, substituted naphthyl, isoquinolinyl, substituted isoquinolinyl, quinolinyl and substituted quinolinyl.

24. (Currently Amended) A method as in claim 1, wherein M is substituted by at least one substituent selected from the group consisting of $S(O)_qR^1$, $SO_2NR^1R^2$, $C(O)R^1$, $C(O)OR^1$, and $C(O)NR^1R^2$ wherein q, R^1 and R^2 are independently as defined in claim 1.

25. (Previously Presented) A method of claim 20 wherein M is additionally substituted by one or more substituents selected from the group consisting of C_1 - C_{10} alkyl, up to per halo substituted C_1 - C_{10} alkyl, -CN, -OH, halogen, C_1 - C_{10} alkoxy and up to per halo substituted C_1 - C_{10} alkoxy.

26. (Previously Presented) A method as in claim 20 wherein L of formula I is -O-, -S-, -NH-, -N(CH₃)-, -NHCH₂-, -NC₂H₄-, -CH₂-, -C(O)-, -CH(OH)-, -NHC(O)N(CH₃)CH₂-, -NCH₃C(O)N(CH₃)CH₂-, -CH₂C(O)N(CH₃)-, C(O)N(CH₃)CH₂-, -NHC(O)-, -N(CH₃)C(O)-, -C(O)N(CH₃)-, -C(O)NH-, -CH₂O-, -CH₂S-, -CH₂N(CH₃)-, -OCH₂-, -CHF-, -CF₂-, -CCl₂-, -S-CH₂- or -N(CH₃)CH₂-.

27. (Original) A method of claim 1 wherein L of formula I is selected from the group consisting of -O-, -S-, -N(R³⁵)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO, where m= 1-3 and R³⁵ is hydrogen, C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy or up to per halo substituted C₁-C₁₀ alkoxy.

28. (Original) A method of claim 1 wherein M is substituted by -C(O)NR¹R² and R¹ and R² are as defined in claim 1.

29. (Previously Presented) A method of claim 18 wherein M is

- a saturated C₃-C₆ monocyclic carbocyclic moiety selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentanyl, and cyclohexanyl;
- a saturated C₈-C₁₀ bicyclic carbocyclic moiety selected from the group consisting of bicyclopentanyl and bicyclohexanyl;
- a partially saturated C₃-C₆ monocyclic carbocyclic moiety selected from the group consisting of cyclopentenyl, cyclohexenyl and cyclohexadienyl;
- the partially saturated C₈-C₁₀ bicyclic carbocyclic moiety bicyclohexenyl;
- a substituted naphthyl group selected from benzocyclobutanyl, indanyl, indenyl, dihydronaphthyl and tetrahydronaphthyl; or

an 8 to 10 membered bicyclic heteroaryl group selected from cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridiazine, cyclohexanopyridiazine, cyclopentanthiophene and cyclohexanthiophene.

30. (Previously Presented) A method as in claim 1 wherein the disease that is treated is a VEGFR-2 mediated disorder.

31. (Previously Presented) A method as in claim 1 wherein the disease that is treated is a VEGFR-1 mediated disorder.

32. (Canceled)

33. (Previously Presented) A method as in claim 1 wherein the disease that is treated is a VEGFR-3 mediated disorder.

34. (New) A method for treating or preventing a disease in a human or other mammal regulated by tyrosine kinase (associated with an aberration in the tyrosine kinase signal transduction pathway) comprising administering to a human or other mammal in need thereof a compound of Formula I, a salt form of a compound of Formula I, an isomer of a compound of Formula I or a prodrug of a compound of Formula I



wherein A is selected from the group consisting of

(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro; and

(iv) 8 to 10 membered bicyclic heteroaryl group in which the first ring is bonded to the NH of Figure I and contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S, and the second ring is fused to the first ring using 3 to 4 carbon atoms, the bicyclic heteroaryl group is optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, and nitro,

B is selected from the group consisting of

(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of -L-M, C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched

haloalkyl, C₁-C₃ alkoxy, hydroxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino, halogen, cyano, and nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents independently selected from the group consisting of -L-M, C₁-C₅ linear or branched alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₃ alkoxy, hydroxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino, halogen, cyano, and nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of -L-M, C₁-C₅ linear or branched alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₃ alkoxy, hydroxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino, halogen, cyano, and nitro; and

(iv) 8 to 10 membered bicyclic heteroaryl groups having 1-6 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of -L-M, C₁-C₅ linear or branched alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₃ alkoxy, hydroxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino, halogen, cyano, and nitro;

L is selected from the group consisting of:

- (a) $-(CH_2)_m-O-(CH_2)_l-$,
- (b) $-(CH_2)_m-(CH_2)_l-$,
- (c) $-(CH_2)_m-C(O)-(CH_2)_l-$,
- (d) $-(CH_2)_m-NR^3-(CH_2)_l-$,
- (e) $-(CH_2)_m-NR^3C(O)-(CH_2)_l-$,

- (f) $-(\text{CH}_2)_m-\text{S}-(\text{CH}_2)_l-$,
- (g) $-(\text{CH}_2)_m-\text{C}(\text{O})\text{NR}^3-(\text{CH}_2)_l-$,
- (h) $-(\text{CH}_2)_m-\text{CF}_2-(\text{CH}_2)_l-$,
- (i) $-(\text{CH}_2)_m-\text{CCl}_2-(\text{CH}_2)_l-$,
- (j) $-(\text{CH}_2)_m-\text{CHF}-(\text{CH}_2)_l-$,
- (k) $-(\text{CH}_2)_m-\text{CH}(\text{OH})-(\text{CH}_2)_l-$;
- (l) $-(\text{CH}_2)_m-\text{C}\equiv\text{C}-(\text{CH}_2)_l-$;
- (m) $-(\text{CH}_2)_m-\text{CH}=\text{CH}-(\text{CH}_2)_l-$; and
- (n) a single bond, where m and l are 0;
- (o) $-(\text{CH}_2)_m-\text{CR}^4\text{R}^5-(\text{CH}_2)_l-$;

wherein the variables m and l are integers independently selected from 0-4,

M is selected from the group consisting of:

(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $\text{S}(\text{O})_q\text{R}^1$, $\text{SO}_2\text{NR}^1\text{R}^2$, $\text{NR}^1\text{SO}_2\text{R}^2$, $\text{C}(\text{O})\text{R}^1$, $\text{C}(\text{O})\text{OR}^1$, $\text{C}(\text{O})\text{NR}^1\text{R}^2$, $\text{NR}^1\text{C}(\text{O})\text{R}^2$, $\text{NR}^1\text{C}(\text{O})\text{OR}^2$, halogen, cyano and nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $\text{S}(\text{O})_q\text{R}^1$, $\text{SO}_2\text{NR}^1\text{R}^2$, $\text{NR}^1\text{SO}_2\text{R}^2$, $\text{C}(\text{O})\text{R}^1$, $\text{C}(\text{O})\text{OR}^1$, $\text{C}(\text{O})\text{NR}^1\text{R}^2$, $\text{NR}^1\text{C}(\text{O})\text{R}^2$, $\text{NR}^1\text{C}(\text{O})\text{OR}^2$, halogen, cyano and nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $\text{S}(\text{O})_q\text{R}^1$, $\text{SO}_2\text{NR}^1\text{R}^2$, $\text{NR}^1\text{SO}_2\text{R}^2$, $\text{C}(\text{O})\text{R}^1$, $\text{C}(\text{O})\text{OR}^1$, $\text{C}(\text{O})\text{NR}^1\text{R}^2$, $\text{NR}^1\text{C}(\text{O})\text{R}^2$, $\text{NR}^1\text{C}(\text{O})\text{OR}^2$, halogen, cyano, nitro and oxides;

(iv) 8 to 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, nitro and oxides;

(v) saturated and partially saturated C_3 - C_6 monocyclic carbocyclic moiety optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano and nitro;

(vi) saturated and partially saturated C_8 - C_{10} bicyclic carbocyclic moiety, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano and nitro;

(vii) saturated and partially saturated 5 and 6 membered monocyclic heterocyclic moiety, having 1-3 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, nitro, and oxides; and

(viii) saturated and partially saturated 8 to 10 membered bicyclic heterocyclic moiety, having 1-6 heteroatoms independently selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group

consisting of R^1 , OR^1 , NR^1R^2 , $S(O)_qR^1$, $SO_2NR^1R^2$, $NR^1SO_2R^2$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, nitro, and oxides;

wherein each $R^1 - R^5$ is independently selected from the group consisting of:

- (a) hydrogen,
- (b) C_1-C_6 alkyl, wherein said alkyl is optionally substituted with halogen up to per-halo;
- (c) phenyl;
- (d) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms selected from the group consisting of O, N and S;
- (e) C_1-C_3 alkyl-phenyl wherein said alkyl moiety is optionally substituted with halogen up to per-halo; and
- (f) C_1-C_3 alkyl-heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S, wherein said heteroaryl group is a 5-6 membered monocyclic heteroaryl or a 8-10 membered bicyclic heteroaryl, and wherein said alkyl moiety is optionally substituted with halogen up to per-halo,

wherein each $R^1 - R^5$, when not hydrogen is optionally substituted with 1-3 substituents independently selected from the group consisting of C_1-C_5 linear branched or cyclic alkyl, wherein said alkyl is optionally substituted with halogen up to per-halo, C_1-C_3 alkoxy, wherein said alkoxy is optionally substituted with halogen up to per-halo, hydroxy, amino, C_1-C_3 alkylamino, C_2-C_6 dialkylamino, halogen, cyano, and nitro; and

each variable q is independently selected from 0, 1, or 2.

35. (New) A method as in claim 1, wherein the oxides are selected from the group consisting of -O, -O⁻, and -OH.

36. (New) A method as in claim 1, wherein the C₁-C₆ alkyl of the group for R¹-R⁵ is a C₁-C₅ linear, branched or cyclic alkyl.

37. (New) A method as in claim 18, wherein the oxides are selected from the group consisting of -O, -O⁻, and -OH.

38. (New) A method as in claim 18, wherein the C₁-C₆ alkyl of the group for R¹-R⁵ is a C₁-C₅ linear, branched or cyclic alkyl.

09/993,647

Appl. No.
Amdt. dated October 30, 2006
Reply to Office Action of, June 29, 2006

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-73. (Canceled)

74. (Previously Presented) A method for the treatment of a solid tumor in a human or animal comprising administering
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea, or
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

75.-80. (Canceled)

81. (Previously Presented) A method for the treatment of a carcinoma, myeloid disorder or adenoma in a human or animal comprising administering
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea, or
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl).

82.-86. (Canceled)

87. (Previously Presented) A method for the treatment of carcinoma of the lung, pancreas,

Amdt. dated October 30, 2006
Reply to Office Action of, June 29, 2006

thyroid, bladder or colon in a human or animal comprising administering

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea, or

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl).

88.-92. (Canceled)

93. (Previously Presented) A method as in claim 81 for the treatment of myeloid leukemia or villous colon adenoma.

94-98. (Canceled)

99. (Previously Presented) A method of claim 74 wherein a human is treated.

100. (Previously Presented) A method of claim 87 for the treatment of carcinoma of the lung in a human.

101. (Previously Presented) A method of claim 87 for the treatment of carcinoma of the pancreas in a human.

102. (Previously Presented) A method of claim 87 for the treatment of carcinoma of the thyroid in a human.

Amdt. dated October 30, 2006
Reply to Office Action of, June 29, 2006

103. (Previously Presented) A method of claim 87 for the treatment of carcinoma of the bladder in a human.

104. (Previously Presented) A method of claim 87 for the treatment of carcinoma of the colon in a human.

105. (Previously Presented) A method of claim 99 comprising administering *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

106. (Previously Presented) A method for the treatment of a solid tumor in a human or animal comprising administering a tosylate salt of *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

107. (Previously Presented) A method for the treatment of a carcinoma, myeloid disorder or adenoma in a human or animal comprising administering a tosylate salt of *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

108. (Previously Presented) A method for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon in a human or animal comprising administering a tosylate salt of *N*-(4-

Amdt. dated October 30, 2006
Reply to Office Action of, June 29, 2006

chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl)
urea.

109. (Previously Presented) A method as in claim 107 for the treatment of myeloid leukemia or villous colon adenoma.

110. (Previously Presented) A method of claim 106 wherein a human is treated.

111. (Previously Presented) A method of claim 108 for the treatment of carcinoma of the lung in a human.

112. (Previously Presented) A method of claim 108 for the treatment of carcinoma of the pancreas in a human.

113. (Previously Presented) A method of claim 108 for the treatment of carcinoma of the thyroid in a human.

114. (Previously Presented) A method of claim 108 for the treatment of carcinoma of the bladder in a human.

Amdt. dated October 30, 2006
Reply to Office Action of, June 29, 2006

115. (Previously Presented) A method of claim 108 for the treatment of carcinoma of the colon in a human.

116. (Currently Amended) A method of claim 109 comprising administering a tosylate salt of *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

117. (New) A method for inhibiting RAF-kinase in a human or mammal comprising administering a tosylate of salt *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea, or *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

10/042,203

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: :
Bernd RIEDL et al. : Group Art Unit: TO BE ASSIGNED
Serial No.: TO BE ASSIGNED : Examiner: TO BE ASSIGNED
Filed: January 11, 2002 :
For: ω -CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF
KINASE INHIBITORS

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the accompanying application as follows.

IN THE SPECIFICATION

Page 1, line 1, after the title insert

--Priority is claimed to provisional application Serial No. (Unassigned), filed on
January 12, 2001.--

IN THE CLAIMS

Please cancel claims 1-49 and 55-67 without prejudice or disclaimer.

Please amend claims 50-59 as follows.

Claim 50. (Amended) A pharmaceutically acceptable salt of claim 69 selected from the group consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid;

and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

Claim 51. (Amended) A pharmaceutically acceptable salt of claim 70 selected from the group consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

Claim 52. (Amended) A pharmaceutically acceptable salt of claim 71 selected from the group consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

Claim 53. (Amended) A pharmaceutically acceptable salt of claim 72 selected from the group consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

Claim 54. (Amended) A pharmaceutically acceptable salt of claim 73 selected from the group consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

Please add new claims 68-109 as follows.

--68. A pharmaceutically acceptable salt of a compound selected from the group consisting of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N*=(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*=(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea and their pharmaceutically acceptable salts.

69. A pharmaceutically acceptable salt of the compound

N-(5-*tert*-butyl-2-methoxy phenyl)-*N*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea.

70. A pharmaceutically acceptable salt of the compound

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

71. A pharmaceutically acceptable salt of the compound

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

72. A pharmaceutically acceptable salt of the compound

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

73. A pharmaceutically acceptable salt of the compound

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

74. A method for the treatment of a cancerous cell growth mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of a compound selected from the group consisting of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl)
urea;
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*=(3-(2-(*N*-methylcarbamoyl)-4-
pyridyloxy)phenyl) urea.

75. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF
kinase comprising administering a pharmaceutically acceptable salt of
N-(5-tert-butyl-2-methoxy phenyl)-*N*=(4-(4-methoxy-3-(*N*-methyl
carbamoyl)phenoxy)phenyl) urea.

76. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF
kinase comprising administering a pharmaceutically acceptable salt of
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*=(4-(2-(*N*-methylcarbamoyl)-4-
pyridyloxy)phenyl) urea.

77. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF
kinase comprising administering a pharmaceutically acceptable salt of
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

78. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF
kinase comprising administering a pharmaceutically acceptable salt of
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl)
urea.

79. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF
kinase comprising administering a pharmaceutically acceptable salt of
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*=(3-(2-(*N*-methylcarbamoyl)-4-
pyridyloxy)phenyl) urea.

80. A method as in claim 74 for the treatment of solid cancers.

81. A method as in claim 74 for the treatment of carcinomas, myleoid disorders or adenomas.
82. A method as in claim 75 for the treatment of carcinomas, myleoid disorders or adenomas.
83. A method as in claim 76 for the treatment of carcinomas, myleoid disorders or adenomas.
84. A method as in claim 77 for the treatment of carcinomas, myleoid disorders or adenomas.
85. A method as in claim 78 for the treatment of carcinomas, myleoid disorders or adenomas.
86. A method as in claim 79 for the treatment of carcinomas, myleoid disorders or adenomas.
87. A method as in claim 74 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
88. A method as in claim 75 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
89. A method as in claim 76 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
90. A method as in claim 77 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
91. A method as in claim 78 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
92. A method as in claim 79 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

93. A method as in claim 74 for the treatment of myeloid leukemia or villous colon adenomas.

94. A method as in claim 75 for the treatment of myeloid leukemia or villous colon adenomas.

95. A method as in claim 76 for the treatment of myeloid leukemia or villous colon adenomas.

96. A method as in claim 77 for the treatment of myeloid leukemia or villous colon adenomas.

97. A method as in claim 78 for the treatment of myeloid leukemia or villous colon adenomas.

98. A method as in claim 79 for the treatment of myeloid leukemia or villous colon adenomas.

99. A method as in claim 74 wherein the pharmaceutically acceptable salt administered is selected from the group of salts consisting of

- a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and
- b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

100. A method as in claim 75 where the pharmaceutical acceptable salt administered is the tosylate salt of

N-(5-*tert*-butyl-2-methoxy phenyl)-*N*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea.

101. A method as in claim 76 where the pharmaceutical acceptable salt administered is the tosylate salt of

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

102. A method as in claim 77 where the pharmaceutical acceptable salt administered is the tosylate salt of

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

103. A method as in claim 78 where the pharmaceutical acceptable salt administered is the tosylate salt of

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

104. A method as in claim 79 where the pharmaceutical acceptable salt administered is the tosylate salt of

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

105. A pharmaceutical acceptable salt as in claim 69 which is the tosylate salt of

N-(5-*tert*-butyl-2-methoxy phenyl)-*N*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea.

106. A pharmaceutical acceptable salt as in claim 70 which is the tosylate salt of

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

107. A pharmaceutical acceptable salt as in claim 71 which is the tosylate salt of *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

108. A pharmaceutical acceptable salt as in claim 72 which is the tosylate salt of *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.


109. A pharmaceutical acceptable salt as in claim 73 which is the tosylate salt of *N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*=(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.--

Bayle-35

10/361,859

(viii) Claims Appendix

1. (Previously Presented) A compound of formula (I),



wherein,

- Y is OR^1 or NHR^2 ,
 Hal is chlorine or bromine,
 R^1 is H or C_1-C_6 alkyl,
 R^2 is H, OH, CH_3 or CH_2OH ,
 Z^1 and Z^2 are each H or OH, wherein only one of Z^1 or Z^2 can be OH,
 X^1 to X^7 are each, independently, H, OH or $O(CO)C_1-C_4$ alkyl, and
 n is 0 or 1,

with the proviso that at least one of conditions a-c is met,

- a) Z^1 or Z^2 is OH,
- b) Y is NHR^2 and R^2 is OH,
- c) n is 1,

or a salt thereof, or an isolated stereoisomer thereof.

2. (Original) A compound of claim 1 wherein n of formula I is 1.

3. **(Original)** A compound of claim 2 wherein Y is NHR^2 and R^2 is H or CH_3 ,
4. **(Original)** A compound of claim 2 wherein
- a) X^1 to X^7 are each H, or
 - b) Z^1 and Z^2 are each H.
5. **(Original)** A compound of claim 2 wherein
- a) X^1 to X^7 are each H, or
 - b) Z^1 is H and Z^2 is OH or Z^1 is OH and Z^2 is H, or
 - c) X^1 to X^7 and Z^1 are each H and Z^2 is OH or
 - d) X^1 to X^7 and Z^2 are each H and Z^1 is OH.
6. **(Original)** A compound of claim 2, wherein at least one of X^1 to X^7 is OH or $\text{O}(\text{CO})\text{C}_1\text{-C}_4$ alkyl.
7. **(Original)** A compound of claim 2, wherein Y is NHR^2 and R^2 is CH_2OH or OH.
8. **(Original)** A compound of claim 2 wherein Y is OH.
9. **(Original)** A compound of claim 1, wherein Z^1 is H and Z^2 is OH or Z^1 is OH and Z^2 is H.

10. (Original) A compound of claim 9, wherein n is 0.
11. (Original) A compound of claim 10, wherein R^2 is H or CH_3 .
12. (Original) A compound of claim 10, wherein X^1 to X^7 are each H.
13. (Original) A compound of claim 10, wherein at least one of X^1 to X^7 is OH or $O(CO)C_1-C_4$ alkyl.
14. (Original) A compound of claim 10, wherein R^2 is CH_2OH or OH.
15. (Original) A compound of claim 10, wherein Y is OH.
16. (Original) A compound of claim 1, wherein in formula (I), Y is NHR^2 and R^2 is OH.
17. (Original) A compound of claim 16, wherein n is 0.
18. (Previously Presented) A compound of claim 17, wherein X^1 to X^7 are each H.
19. (Original) A compound of claim 17, wherein Z^1 is H and Z^2 is OH or Z^1 is OH and Z^2 is H.

20. (Original) A compound of claim 17, wherein at least one of X^1 to X^7 is OH or $O(CO)C_1-C_4$ alkyl.

21. (Original) A compound of claim 1, wherein in formula (I), Y is OH.

22. (Original) A compound of claim 21, wherein n is 0.

23. (Original) A compound of claim 22, wherein X^1 to X^7 are each H.

24. (Original) A compound of claim 22, wherein Z^2 is H and Z^1 is OH.


25. (Original) A compound of claim 22, wherein Z^1 is H and Z^2 is OH.

26. (Original) A compound of claim 22, wherein at least one of X^1 to X^7 is OH or $O(CO)C_1-C_4$ alkyl.

27. (Original) A compound selected from the group consisting of :
4-{4-[(4-chloro-3-(trifluoromethyl)phenyl)amino]carbonyl]amino]phenoxy}-N-methyl-2-pyridine carboxamide 1-oxide,
4-{4-[(4-chloro-3-(trifluoromethyl)phenyl)amino]carbonyl]amino]phenoxy}-N-hydroxymethyl-2-pyridine carboxamide 1-oxide,
4-{4-[(4-bromo-3-(trifluoromethyl)phenyl)amino]carbonyl]amino]phenoxy}-N-methyl-2-pyridine carboxamide 1-oxide,

4-{4-[(4-bromo-3-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenoxy}-N-hydroxymethyl-2-pyridine carboxamide 1-oxide,
 4-{4-[(4-chloro-3-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenoxy}-2-pyridine carboxamide 1-oxide,
 4-{4-[(4-bromo-3-(trifluoromethyl)phenyl)amino]carbonyl}amino]phenoxy}-2-pyridine carboxamide 1-oxide, salts thereof and stereoisomers thereof.

28. (Previously Presented) A compound of formula (II), or a salt or stereoisomer thereof,



wherein,

Y is OR¹ or NHR²,

Hal is chlorine or bromine,

R¹ is H or C₁-C₆ alkyl,

R² is H, OH, CH₃ or CH₂OH,

Z¹ and Z² are each H or OH, wherein only one of Z¹ or Z² is OH,

X⁴ to X⁷ are each, independently, H, OH or O(CO)C₁-C₄ alkyl, and

n is 0 or 1,

with the proviso that at least one of conditions a-c is met,

a) Z¹ or Z² is OH,

b) Y is NHR^2 and R^2 is OH,

c) n is 1.

29. (Original) A compound of claim 28, wherein in formula (II), n is 1.

30. (Original) A compound of claim 29, wherein in formula (II), Z^1 and Z^2 are each H.

31. (Original) A compound of claim 30, wherein in formula (II), at least one of X^4 to X^7 is OH.

32. (Original) A compound of claim 30, wherein in formula (II), Y is NHR^2 and R^2 is H or CH_3 .

33. (Original) A compound of claim 28, wherein in formula (II), n is 0 and Z^1 is H and Z^2 is OH or Z^1 is OH and Z^2 is H.

34. (Original) A compound of claim 28, wherein in formula (II), n is 0, Z^1 and Z^2 are each H, and at least one of X^4 to X^7 is OH.


35. (Original) A compound of claim 33, wherein in formula (II), at least one of X^4 to X^7 is OH.

36. (Original) A compound of claim 33, wherein in formula (II), Y is NHR^2 and R^2 is H or CH_3 .

37. (Original) A compound of claim 33, wherein in formula (II) Y is NHR^2 and R^2 is OH.

38 (Original) A compound of claim 37, wherein in formula (II), at least one of X^4 to X^7 is OH.

39. (Previously Presented) A compound of formula (III), or a salt or isolated stereoisomer thereof,



wherein,

Y is OR^1 or NHR^2 ,

Hal is chlorine or bromine,

R^1 is H or $\text{C}_1\text{-C}_6$ alkyl,

R^2 is H, OH, CH_3 or CH_2OH ,

Z^1 and Z^2 are each H or OH, wherein only one of Z^1 or Z^2 can be OH, and

n is 0 or 1,

with the proviso that at least one of conditions a-c is met,

- a) Z^1 or Z^2 is OH,
- b) Y is NHR^2 and R^2 is OH,
- c). n is 1.

40. (Original) A compound of claim 39, wherein in formula (III), n is 1 and Z^1 and Z^2 are each H.

41. (Original) A compound of claim 40, wherein in formula (III), Y is NHR^2 and R^2 is H or CH_3 ,

42. (Original) A compound of claim 39, wherein in formula (III), n is 0 and Z^1 is H and Z^2 is OH or Z^1 is OH and Z^2 is H,

43. (Original) A compound of claim 42, wherein in formula (III), Y is NHR^2 and R^2 is H or CH_3 .

44. (Original) A compound of claim 39, wherein in formula (III), Y is OH.

45. (Cancelled)

46. (Previously Presented) A method of preparing compounds of claim 1, comprising oxidizing:

4-{4-[(4-chloro-3-(trifluoromethyl) phenyl)amino]carbonyl]amino]phenoxy}-N-methyl-2-pyridine carboxamide,

4-{4-[(4-bromo-3-(trifluoromethyl) phenyl)amino]carbonyl]amino]phenoxy}-N-methyl-2-pyridine carboxamide,

4-{4-[(4-chloro-3-trifluoromethyl) phenyl]amino}carbonyl]amino]phenoxy}-2-pyridine carboxamide, or

- 4-{4-[(4-bromo-3-(trifluoromethyl) phenyl]amino}carbonyl)amino] phenoxy}-2-pyridine carboxamide to :
- a) replace one or more of the phenyl hydrogens at the positions represented by X¹ to X⁷ with a hydroxyl group,
 - b) hydroxylate the N-methyl amide into a hydroxymethyl amide or hydroxamic acid,
 - c) demethylate the N-methyl amide into an unsubstituted amide,
 - d) replace one or more of the urea nitrogens (=NH) with a hydroxyl group to form an N-hydroxyurea (=NOH),
 - e) hydrolyze the N-methyl amide into a carboxylic acid,
 - f) oxidize the pyridyl ring nitrogen to form the corresponding pyridine-1-oxide, or
 - g) provide a combination of two or more of a) - f);
- with the proviso that at least one of b), d) and f) is performed.

47. **(Original)** A method as in claim 46 wherein oxidation of 4-{4-[(4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl)amino]phenoxy}-N-methyl-2-pyridine carboxamide,

4-{4-[(4-bromo-3-(trifluoromethyl) phenyl]amino}carbonyl)amino]phenoxy}-N-methyl-2-pyridine carboxamide,

4-{4-[(4-chloro-3-trifluoromethyl) phenyl]amino}carbonyl)amino]phenoxy}-2-pyridine carboxamide, or

4-{4-[(4-bromo-3-(trifluoromethyl)

phenyl]amino}carbonyl)amino] phenoxy}-2-pyridine carboxamide replaces one or more hydrogens at the positions represented by X¹ to X⁷ with a hydroxyl group and at least one of the hydroxyl groups in the X¹ to X⁷ positions is esterified.

48. (Original) A method as in claim 46 which prepares

4-{4-[[{4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl)amino]phenoxy}-N-methyl-2-pyridine carboxamide 1-oxide, 4-{4-[[{4-bromo-3-(trifluoromethyl)phenyl]amino} carbonyl)amino]phenoxy}-N-methyl-2-pyridine carboxamide 1-oxide,

4-{4-[[{4-chloro-3-(trifluoromethyl)phenyl] amino}carbonyl)amino]phenoxy}2-pyridine carboxamide 1-oxide,

4-{4-[[{4-bromo-3-(trifluoromethyl)phenyl] amino}carbonyl)amino]phenoxy}2-pyridine carboxamide 1-oxide, or a pharmaceutically acceptable salt of one of these oxides, or an isolated stereoisomer of one of these oxides.

49. (Original) A pharmaceutical composition comprising an effective amount of at least one compound of claim 1 and a physiologically acceptable carrier.

50. (Original) A pharmaceutical composition comprising an effective amount of

4-{4-[[{4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl)amino]phenoxy}-N-methyl-2-pyridine carboxamide 1-oxide, 4-{4-[[{4-bromo-3-(trifluoromethyl)phenyl]amino} carbonyl)amino]phenoxy}-N-methyl-2-pyridine carboxamide 1-oxide,

4-{4-[[{4-chloro-3-(trifluoromethyl)phenyl] amino}carbonyl)amino]phenoxy}2-

pyridine carboxamide 1-oxide,

4-{4-[[{4-bromo-3-(trifluoromethyl)phenyl] amino} carbonyl)amino]phenoxy} 2-

pyridine carboxamide 1-oxide or

a pharmaceutically acceptable salt of one of these oxides, an isolated stereoisomer of one of these oxides or a mixture thereof and a physiologically acceptable carrier.

51. (Original) A method of treating or preventing osteoporosis, inflammation, and angiogenesis disorders, with the exclusion of cancer, in a mammal by administering an effective amount of a compound of claim 1 to said mammal.

52. (Original) A method as in claim 51 wherein the compound of claim 1 administered is within a pharmaceutical composition comprising an effective amount of a compound of claim 1 and a physiologically acceptable carrier.

53. (Original) A method of treating or preventing a hyper-proliferative disorder in a mammal comprising administering an effective amount of a compound of claim 1 to said mammal.

54. (Original) A method of treating or preventing a hyper-proliferative disorder in a mammal comprising administering an effective amount of a compound of claim 27 to said mammal.

55. (Withdrawn) A method of treating or preventing a hyper-proliferative disorder in a mammal comprising administering to said mammal a) an effective amount of a compound of claim 1 and b) an additional anti-proliferative agent.

56. (Withdrawn) A method as in claim 55 wherein the compound of claim 1 administered is within a pharmaceutical composition comprising an effective amount of a compound of claim 1 and a physiologically acceptable carrier.

57. (Withdrawn) A method as in claim 56 wherein the pharmaceutical composition comprises an effective amount of a compound of claim 1, a physiologically acceptable carrier and the additional anti-proliferative agent.

58. (Withdrawn) A method as in claim 56 wherein the additional anti-proliferative agent administered is within a pharmaceutical composition separate from the pharmaceutical composition comprising an effective amount of a compound of claim 1 and a physiologically acceptable carrier.

59. (Withdrawn) A method as in claim 56 wherein the additional anti-proliferative agent is selected from the group consisting of asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycine), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine,

raloxifen, streptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, vindesine,

aminoglutethimide, L-asparaginase, azathioprine, 5-azacytidine cladribine, busulfan, diethylstilbestrol, 2',2'-difluorodeoxycytidine, docetaxel, erythrohydroxynonyladenine, ethinyl estradiol, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphate, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon, medroxyprogesterone acetate, megestrol acetate, melphalan, mitotane, paclitaxel, oxaliplatin, gemcitabone, gefinitib, taxotere, BCNU, CCNU, DTIC, ara A, ara C, herceptin, actinomycin D, pentostatin, N-phosphonoacetyl-L-aspartate (PALA), plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, uridine, and vinorelbine.

60. (Withdrawn) A method of treating or preventing osteoporosis, inflammation, and angiogenesis disorders, with the exclusion of raf-mediated cancer, in a mammal by administering an effective amount of a compound of claim 27 to said mammal.

61. (Withdrawn) A method of treating or preventing cancer by administering to a mammal

- a) an effective amount of a compound of claim 1, and
- b) a cytotoxic agent or cytostatic chemotherapeutic agent.

62. (Withdrawn) A method of claim 61 wherein the compound of claim 1 administered is within a pharmaceutical composition comprising an effective amount of a compound of claim 1 and a physiologically acceptable carrier.

63. (Withdrawn) A method of claim 62 wherein the pharmaceutical composition comprises an effective amount of a compound of claim 1, a physiologically acceptable carrier and the cytotoxic agent or cytostatic chemotherapeutic agent.

64. (Withdrawn) A method of claim 62 wherein the cytotoxic agent or cytostatic chemotherapeutic agent administered is within a pharmaceutical composition separate from the pharmaceutical composition comprising an effective amount of a compound of claim 1 and a physiologically acceptable carrier.

65. (Withdrawn) A method as in claim 61 wherein the cytotoxic or cytostatic chemotherapeutic agent is selected from the group consisting of DNA topoisomerase I and II inhibitors, DNA intercalators, alkylating agents, microtubule disruptors, hormone and growth factor receptor agonists or antagonists, other kinase inhibitors and anti-metabolites.

66. (Withdrawn) A kit comprising a separate dose of the cytotoxic or cytostatic agent and, a separate dose of a compound of claim 1.

67. **(Withdrawn)** A method of treating or preventing a hyper-proliferative disorder in a mammal comprising administering to said mammal a) an effective amount of a compound of claim 27 and b) an additional anti-proliferative agent.

68. **(Withdrawn)** A method wherein the compound of claim 27 administered is within a pharmaceutical composition comprising an effective amount of a compound of claim 27 and a physiologically acceptable carrier.

69. **(Withdrawn)** A method wherein the pharmaceutical composition comprises an effective amount of a compound of claim 27, a physiologically acceptable carrier and the additional anti-proliferative agent.


70. **(Withdrawn)** A method wherein the additional anti-proliferative agent administered is within a pharmaceutical composition separate from the pharmaceutical composition comprising an effective amount of a compound of claim 27 and a physiologically acceptable carrier.

71. **(Withdrawn)** A method as in claim 68 wherein the additional anti-proliferative agent is selected from the group consisting of asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycine), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine,

raloxifen, streptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, vindesine,


aminoglutethimide, L-asparaginase, azathioprine, 5-azacytidine cladribine, busulfan, diethylstilbestrol, 2',2'-difluorodeoxycytidine, docetaxel, erythrohydroxynonyladenine, ethinyl estradiol, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphate, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon, medroxyprogesterone acetate, megestrol acetate, melphalan, mitotane, paclitaxel, oxaliplatin, gemcitabone, gefinitib, taxotere, BCNU, CCNU, DTIC, ara A, ara C, herceptin, actinomycin D, pentostatin, N-phosphonoacetyl-L-aspartate (PALA), plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, uridine, and vinorelbine.

72. (Original) A method of preparing N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{4-[2-(N-methylcarbamoyl)-1-oxo-(4-pyridyloxy)]phenyl} urea



comprising chemically oxidizing N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{4-[2-(N-methylcarbamoyl)(4-pyridyloxy)]phenyl} urea in solution.

73. (Original) method of preparing N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{4-[2-carbamoyl-1-oxo-(4-pyridyloxy)]phenyl} urea



comprising chemically oxidizing N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{4-[2-carbamoyl-(4-pyridyloxy)]phenyl} urea in solution.

74. (Previously Presented) A derivative of one of the following compounds:

4-{4-[(4-chloro-3-(trifluoromethyl) phenyl)amino]carbonyl)amino]phenoxy}-
N-methyl-2-pyridine carboxamide, or

4-{4-[(4-bromo-3-(trifluoromethyl) phenyl)amino]carbonyl)amino]phenoxy}-
N-methyl-2-pyridine carboxamide, or

4-{4-[(4-chloro-3-trifluoromethyl)
phenyl]amino}carbonyl)amino]phenoxy}-2-pyridine carboxamide, or

4-{4-[(4-bromo-3-(trifluoromethyl)
phenyl]amino}carbonyl)amino] phenoxy}-2-pyridine carboxamide
obtained by oxidizing the compound.

75. (Previously Presented) A derivative of one of the following compounds:

4-{4-[(4-chloro-3-(trifluoromethyl) phenyl)amino]carbonyl)amino]phenoxy}-
N-methyl-2-pyridine carboxamide,

4-{4-[(4-bromo-3-(trifluoromethyl) phenyl)amino]carbonyl)amino]phenoxy}-
N-methyl-2-pyridine carboxamide,

4-{4-[(4-chloro-3-trifluoromethyl)
phenyl]amino}carbonyl)amino]phenoxy}-2-pyridine carboxamide, or

4-{4-[(4-bromo-3-(trifluoromethyl)
phenyl]amino}carbonyl)amino] phenoxy}-2-pyridine carboxamide; wherein said
derivative is obtained by

- a) replacing one or more of the phenyl hydrogens at the positions represented by X¹ to X⁷ with a hydroxyl group,
 - b) hydroxylating the N-methyl amide where present, into a hydroxymethyl amide or hydroxamic acid,
 - c) replacing one or more of the urea nitrogens (=NH) with a hydroxyl group to form an N-hydroxyurea (=NOH),
 - d) hydrolyzing the N-methyl amide where present, into a carboxylic acid,
 - e) oxidizing the pyridyl ring nitrogen to form the corresponding pyridine-1-oxide, or
 - f) providing a combination of two or more of a) - e);
- with the proviso that at least one of b), d) and f) is performed.

76. (Previously Presented) A derivative of one of the following compounds:

4-{4-[(4-chloro-3-(trifluoromethyl) phenyl)amino]carbonyl)amino]phenoxy}-
N-methyl-2-pyridine carboxamide,

4-{4-[(4-bromo-3-(trifluoromethyl) phenyl)amino]carbonyl)amino]phenoxy}-
N-methyl-2-pyridine carboxamide,

4-{4-[(4-chloro-3-trifluoromethyl)
phenyl]amino}carbonyl)amino]phenoxy}-2-pyridine carboxamide, or

4-{4-[(4-bromo-3-(trifluoromethyl)
phenyl]amino}carbonyl)amino] phenoxy}-2-pyridine carboxamide

obtained by

a) replacing one or more of the phenyl hydrogens with a hydroxyl group on
one of the compounds above and

b) esterifying at least one of these hydroxyl groups.

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A composition comprising a N-(4-chloro-3-(trifluoromethyl)phenyl-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea or a pharmaceutically acceptable salt thereof and a cytotoxic or cytostatic agent selected from the group consisting of: irinotecan, vinorelbine, gemcitabine, gefitinib, [[;]] paclitaxel, and doxorubicin.
2. (Original) The composition according to claim 1, in combination with one or more pharmaceutically acceptable carrier molecules.
3. (Previously Presented) The composition of claim 1, wherein said pharmaceutically acceptable salt of N-(4-chloro-3-(trifluoromethyl)phenyl-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea is a tosylate salt.
4. (Previously Presented) A composition according to claim 1, in the form of an oral, intramuscular, intravenous, subcutaneous, or parenteral dosage which can range from about 0.1 to about 300 mg/kg of total body weight of N-(4-chloro-3-(trifluoromethyl)phenyl-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea and from about 0.1 to about 300 mg/kg of total body weight of a cytotoxic or a cytostatic agent.
5. (Currently Amended) A method for treating a cancer comprising administering a therapeutically effective amount of a composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea or a

pharmaceutically acceptable salt thereof and a cytotoxic or cytostatic agent selected from the group consisting of: irinotecan, vinorelbine, gemcitabine, gefitinib, [[;]] paclitaxel, and doxorubicin.

6. (Previously Presented) The method of claim 5, wherein said pharmaceutically acceptable salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea is a tosylate salt.

7. (Original) The method of claim 5, wherein said cancer is mediated by raf kinase.

8. (Original) The method of claim 5, wherein said cancer is colon, gastric, lung, pancreatic, ovarian, prostate, leukemia, melanoma, hepatocellular, renal, glioma, mammary, or head and neck cancer.

9. (Previously Presented) The method of claim 5, wherein said composition is administered to a patient at an oral, intramuscular, intravenous, subcutaneous, or parenteral dosage which can range from about 0.1 to about 300 mg/kg of total body weight of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea and from about 0.1 to about 300 mg/kg of total body weight of a cytotoxic or a cytostatic agent.

10. (Previously Presented) A composition comprising a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea and a cytotoxic or cytostatic agent selected from the group consisting of: irinotecan, vinorelbine, gemcitabine, gefitinib, paclitaxel, and doxorubicin.

11. (Currently Amended) A method for treating a cancer comprising administering a therapeutically effective amount of a composition comprising a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)-N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea and a cytotoxic or cytostatic agent selected from the group consisting of: irinotecan, vinorelbine, gemcitabine, gefitinib, paclitaxel, and doxorubicin.

12. (Previously Presented) A method for inhibiting the proliferation of cancer cells in a patient comprising contacting said cancer cells with a pharmaceutical preparation comprising the composition of claim 1.

13. (New) A method according to claim 5, wherein a therapeutically effective amount of a composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea or a pharmaceutically acceptable salt thereof and a cytotoxic or cytostatic agent selected from the group consisting of: irinotecan, vinorelbine, gemcitabine, gefitinib, and paclitaxel are administered.

14. (New) A method according to claim 5, wherein pancreatic tumor is treated by the administration of a therapeutically effective amount of a composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea or a pharmaceutically acceptable salt thereof and gemcitabine.

15. (New) A method according to claim 5, wherein non-small cell lung tumor is treated by the administration of a therapeutically effective amount of a composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-

pyridoxy)phenyl)urea or a pharmaceutically acceptable salt thereof and vinorelbine, or gefitinib.

16. (New) A method according to claim 5, wherein mammary tumor is treated by the administration of a therapeutically effective amount of a composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea or a pharmaceutically acceptable salt thereof and doxorubicin.

17. (New) A method according to claim 5, wherein colon tumor is treated by the administration of a therapeutically effective amount of a composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea or a pharmaceutically acceptable salt thereof and irinotecan.


18. (New) A composition according to claim 10, which comprises a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl-N'-(4-(2-(N-methylcarbamoyl)-4-pyridoxy)phenyl)urea and a cytotoxic or cytostatic agent selected from the group consisting of: irinotecan, vinorelbine, gemcitabine, gefitinib, and paclitaxel.

Bayer - 45A

10/895,985

Claims

1. A compound of Formula (I) or a salt, or a prodrug or a metabolite or an isolated stereoisomer thereof



2. A pharmaceutically acceptable salt of a compound of Formula I of claim 1 which is
- a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or
 - b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.
3. A compound which is 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide, or a salt thereof.
4. A pharmaceutically acceptable salt of a compound of claim 3 which is a basic salt of an organic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic

acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid.

5. A compound which is which is a hydrochloride, benzenesulfonate, or methanesulfonate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-2-fluoro-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

6. A pharmaceutical composition comprising a compound of claim 1 and a physiologically acceptable carrier.

7. A pharmaceutical composition comprising a compound of claim 3 and a physiologically acceptable carrier.

8. A pharmaceutical composition for the treatment of a disease in a human or other mammal regulated by a protein kinase, associated with an aberration in the protein kinase signal transduction pathway comprising a compound of claim 1 and a physiologically acceptable carrier.

9. A pharmaceutical composition for the treatment of a hyper-proliferative disorder comprising a compound of claim 1 and a physiologically acceptable carrier.

10. A pharmaceutical composition for the treatment of a cancerous cell growth comprising a compound of claim 1 and a physiologically acceptable carrier.

11. A pharmaceutical composition which comprises a pharmaceutically acceptable salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-2-fluoro-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea and a physiologically acceptable carrier.

12. A method for regulating tyrosine kinase signal transduction comprising administering to a human or other mammal a compound of claim 1.

13. A method for treating or preventing a disease in a human or other mammal which is regulated by tyrosine kinase and associated with an aberration in the tyrosine kinase signal transduction pathway, said method comprising administering to a human or other mammal a compound of claim 1.

14. A method for treating or preventing a disease in a human and/or other mammal which is a VEGFR-2 mediated disorder, said method comprising administering to a human or other mammal a compound of claim 1.

15. A method for treating or preventing a disease in a human and/or other mammal which is a PDGFR mediated disorder, said method comprising administering to a human or other mammal a compound of claim 1.

16. A method for treating or preventing a disease in a human or other mammal which is a raf-mediated disorder, said method comprising administering to a human or other mammal a compound of claim 1.

17. A method for treating or preventing a disease in a human or other mammal which is a p38-mediated disorder, said method comprising administering to a human or other mammal a compound of claim 1.

18. A method for treating or preventing a disease in a human or other mammal which is a VEGF-mediated disorder, said method comprising administering to a human or other mammal a compound of claim 1.

19. A method for treating or preventing a disease in a human or other mammal which is a hyper-proliferative, inflammatory and/or angiogenesis disorder which comprises administering to a human or other mammal a compound of claim 1.

20. A method for treating or preventing a disease in a human or other mammal which is a hyper-proliferative disorder which comprises administering to a human or other mammal a compound of claim 1.

21. A method as in claim 20, wherein the hyper-proliferative disorder is cancer.

22. A method as in claim 21, wherein said method comprises administering to a human or other mammal a compound of claim 1 in combination with one or several additional anti-cancer agents.

23. A method for treating or preventing a disease in a human or other mammal characterized by abnormal angiogenesis or hyperpermeability processes comprising administering to a human or other mammal a compound of claim 1.

24. A method as in claim 23, for treating or preventing a disease in a human or other mammal characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to a human or other mammal, a compound of claim 1 simultaneously with another anti-angiogenesis agent, either in the same formulation or in separate formulations.

25. A method for treating or preventing one or more of the following conditions in humans and/or other mammals:

tumor growth, retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, age related macular degeneration; rheumatoid arthritis, psoriasis, a bullous disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, or dermatitis herpetiformis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumor metastasis, periodontal disease, corneal ulceration, proteinuria and coronary thrombosis from atherosclerotic plaque, aneurismal aortic, birth control, dystrophic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, temporomandibular joint disease or demyelinating disease of the nervous system,

said method comprising administering to a human or other mammal, a compound of claim 1.

26. A method for treating or preventing one or more of the following conditions in humans and/or other mammals: tumor growth, retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, age related macular degeneration; rheumatoid arthritis, psoriasis, a bullous disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, or dermatitis herpetiformis;

in combination with another condition selected from the group consisting of:

rheumatic fever, bone resorption, postmenopausal osteoporosis, sepsis, gram negative sepsis, septic shock, endotoxic shock, toxic shock syndrome, systemic inflammatory response syndrome, inflammatory bowel disease (Krohn's disease and ulcerative colitis), Jarisch-Herxheimer reaction, asthma, adult respiratory distress syndrome, acute pulmonary fibrotic disease, pulmonary sarcoidosis, allergic respiratory disease, silicosis, coal worker's pneumoconiosis, alveolar injury, hepatic failure, liver disease during acute inflammation, severe alcoholic hepatitis, malaria (*Plasmodium falciparum* malaria and cerebral malaria), non-insulin-dependent diabetes mellitus (NIDDM), congestive heart failure, damage following heart disease, atherosclerosis, Alzheimer's disease, acute encephalitis, brain injury, multiple sclerosis (demyelination and oligiodendrocyte loss in multiple sclerosis), advanced cancer, lymphoid malignancy, pancreatitis, impaired wound healing in infection, inflammation and cancer, myelodysplastic syndromes, systemic lupus erythematosus, biliary cirrhosis, bowel necrosis, radiation injury/ toxicity following administration of monoclonal antibodies, host-versus-graft reaction (ischemia reperfusion injury and allograft rejections of kidney, liver, heart, and skin), lung allograft rejection (obliterative bronchitis) and complications due to total hip replacement,

said method comprising administering to a human or other mammal a compound of claim 1.

27. A method for treating or preventing one or more of the following conditions in humans and/or other mammals: tumor growth, retinopathy, diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, age related macular degeneration; rheumatoid arthritis, psoriasis, bullous disorder associated with subepidermal blister formation, bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis,

in combination with an infectious disease selected from the group consisting of:

tuberculosis, *Helicobacter pylori* infection during peptic ulcer disease, Chaga's disease resulting from *Trypanosoma cruzi* infection, effects of Shiga-like toxin resulting from *E. coli* infection, effects of enterotoxin A resulting from *Staphylococcus* infection, meningococcal infection, and infections from *Borrelia burgdorferi*, *Treponema pallidum*, cytomegalovirus, influenza virus, Theiler's encephalomyelitis virus, and the human immunodeficiency virus (HIV);

said method comprising administering to a human or other mammal a compound of claim 1.

28. A method as in claim 22 wherein the additional anti-cancer agent is selected from the group consisting of asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycin), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone, procarbazine, raloxifen, streptozocin, tamoxifen, thioguanine, topotecan, vinblastine, vincristine, vindesine, aminoglutethimide, L-asparaginase, azathioprine, 5-azacytidine cladribine, busulfan, diethylstilbestrol, 2',2'-difluorodeoxycytidine, docetaxel, erythrohydroxynonyl adenine, ethinyl estradiol, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphate, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon, medroxyprogesterone acetate, megestrol acetate, melphalan, mitotane, paclitaxel, pentostatin, N-phosphonoacetyl-L-aspartate (PALA), plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, uridine, and vinorelbine, oxaliplatin, gemcitabine, capecitabine, epothilone and its natural or synthetic derivatives, tositumomab, trabectedin, and temozolomide, trastuzumab, cetuximab, bevacizumab, pertuzumab, ZD-1839 (Iressa), OSI-774 (Tarceva), CI-1033, GW-2016, CP-724,714, HKI-272, EKB-569, STI-571 (Gleevec), PTK-787, SU-11248, ZD-6474, AG-13736, KRN-951, CP-547,632, CP-673,451, CHIR-258, MLN-518, AZD-2171, PD-325901, ARRY-

142886, suberoylanilide hydroxamic acid (SAHA), LAQ-824, LBH-589, MS-275, FR-901228, bortezomib, and CCI-779.

29. A method as in claim 22 wherein the additional anti-cancer agent is a cytotoxic agent selected from the group consisting of DNA topoisomerase I and II inhibitors, DNA intercalators, alkylating agents, anti-metabolites, cell-cycle blockers, microtubule disruptors, and Eg5 inhibitors.

30. A method as in claim 22 wherein the additional anti-cancer agent is selected from the group consisting of inhibitors of growth factor receptor signaling, histone deacetylase inhibitors, inhibitors of the PKB pathway, inhibitors of the Raf/MEK/ERK pathway, inhibitors of the mTOR pathway, and proteasome inhibitors.

31. A method for treating or preventing one or more of the following conditions in humans and/or other mammals:

rheumatic fever, bone resorption, postmenopausal osteoporosis, sepsis, gram negative sepsis, septic shock, endotoxic shock, toxic shock syndrome, systemic inflammatory response syndrome, inflammatory bowel disease (Krohn's disease and ulcerative colitis), Jarisch-Herxheimer reaction, asthma, adult respiratory distress syndrome, acute pulmonary fibrotic disease, pulmonary sarcoidosis, allergic respiratory disease, silicosis, coal worker's pneumoconiosis, alveolar injury, hepatic failure, liver disease during acute inflammation, severe alcoholic hepatitis, malaria (*Plasmodium falciparum* malaria and cerebral malaria), non-insulin-dependent diabetes mellitus (NIDDM), congestive heart failure, damage following heart disease, atherosclerosis, Alzheimer's disease, acute encephalitis, brain injury, multiple sclerosis (demyelination and oligodendrocyte loss in multiple sclerosis), advanced cancer, lymphoid malignancy, pancreatitis, impaired wound healing in infection, inflammation and cancer, myelodysplastic syndromes, systemic lupus erythematosus, biliary cirrhosis, bowel necrosis, psoriasis, radiation injury/ toxicity following administration of monoclonal antibodies, host-versus-graft reaction (ischemia reperfusion injury and allograft rejections of kidney, liver, heart, and skin), lung allograft rejection (obliterative bronchitis) or complications due to total hip replacement,

said method comprising administering to a human or other mammal, a compound of claim 1.

32. A method for treating or preventing one or more of the following conditions in humans and/or other mammals:

tuberculosis, *Helicobacter pylori* infection during peptic ulcer disease, Chaga's disease resulting from *Trypanosoma cruzi* infection, effects of Shiga-like toxin resulting from *E. coli* infection, effects of enterotoxin A resulting from *Staphylococcus* infection, meningococcal infection, and infections from *Borrelia burgdorferi*, *Treponema pallidum*, cytomegalovirus, influenza virus, Theiler's encephalomyelitis virus, and the human immunodeficiency virus (HIV),

said method comprising administering to a human or other mammal, a compound of claim 1.

33. A method for treating or preventing osteoporosis, inflammation, and angiogenesis disorders, with the exclusion of cancer, in a human and/or other mammal by administering an effective amount of a compound of claim 1 to said mammal.

34. A method for treating or preventing cancer in a human or other mammal which comprises administering to a human or other mammal a single active principle combining inhibition of tumor cell proliferation mediated by the raf / MEK / ERK pathway, and inhibition of angiogenesis mediated by PDGF and VEGF.

35. A method of claim 34 where said inhibition of tumor cell proliferation is caused by inhibition of raf kinase, and said inhibition of angiogenesis is caused by dual inhibition of PDGFR-beta and VEGFR-2 kinases.

36. A method for treating or preventing cancer in a human or other mammal which comprises administering to a human or other mammal a single active principle combining inhibition of tumor cell proliferation mediated by the raf pathway, and inhibition of angiogenesis mediated by PDGF or VEGF.

37. A method of treating and/or preventing a disease and/or condition in a subject in need thereof, comprising administering an effective amount of a compound of claim 1 or 2.

38. A method of claim 37, wherein said method comprises causing tumor regression in a subject or cells therefrom.

39. A method of claim 37, wherein said method comprises inhibiting lymphangiogenesis.

40. A method of claim 37, wherein said method comprises inhibiting angiogenesis.

41. A method of claim 37, wherein said method comprises inhibiting lymphangiogenesis and angiogenesis.

42. A method of claim 37, wherein said method comprises stimulating the proliferation of hematopoietic progenitor cells.

43. A method of claim 37, wherein said method comprises treating a disorder in a mammalian subject mediated by raf, VEGFR-2, VEGFR-3, PDGFR-beta, p38 and/or flt-3.

44. A method of claim 37, wherein said method comprises determining whether a condition can be modulated by said compound, comprising measuring the expression or activity of raf, VEGFR-2, VEGFR-3, PDGFR-beta, p38 and/or flt-3, in a sample comprising cells or a cell extract, wherein said sample is obtained from a subject or cell having said condition, whereby said condition can be modulated by said compound when said expression or activity is different in said condition as compared to a normal control.

45. A method of claim 44, further comprising comparing the expression in said sample to said normal control.

46. A method of claim 37, wherein said method comprises assessing the efficacy of said compound disorder, comprising administering said compound, measuring the expression or activity of raf, VEGFR-2, VEGFR-3, PDGFR-beta, p38, and/or flt-3, and determining the effect of said compound on said expression or activity.

47. A method of claim 37, wherein said method comprises determining the presence of raf, VEGFR-2, VEGFR-3, PDGFR-beta, p38 and/or flt-3 in a sample of a biological material, contacting said sample with said compound, and determining whether said compound binds to said material.

48. A method of claim 37, wherein said method comprises treating a tumor in a subject in need thereof, comprising administering an effective amount of said compound wherein said amount is effective to inhibit tumor cell proliferation and neovascularization.

49. A compound which is a naturally occurring metabolite of the compound of claim 3.

50. A compound of claim 49 where the metabolism site is either one of the two urea nitrogen atoms, or the pyridine nitrogen atom, or the methylamide functionality, or any combination of the above.

51. A compound of claim 49 where either urea nitrogen atom carries a hydroxyl group, and/or the pyridine nitrogen atom is oxidized, and/or the amide functionality is de-methylated.

52. A compound of claim 49 which is selected from:

4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid amide,

4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-1-hydroxy-pyridine-2-carboxylic acid methylamide, or

4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-1-hydroxy-pyridine-2-carboxylic acid amide.

53. A method as in claim 19, where the inflammatory disorder is selected from rheumatoid arthritis, COPD, Crohn's disease and psoriasis.

54. A method for treating or preventing a disease in a human or other mammal which is a flt-3 mediated disorder, said method comprising administering to a human or other mammal a compound of claim 1.

Please type a plus sign (+) inside this box.



PTO/SB/08A (05-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 8

Complete if Known

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER 16P4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	A "Notice of References Cited" from the USPTO for U.S. application 08/995,749.	
	AB	A "Notice of References Cited" from the USPTO for U.S. application 09/083,399.	
	AC AND AD	A "Notice of References Cited" from the USPTO for U.S. application 09/425,228.	
	AE	A "Notice of References Cited" from the USPTO for U.S. application 09/425,229.	
	AF	A "Notice of References Cited" from the USPTO for U.S. application 09/458,015.	
	AG	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232.	
	AH	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232.	
	AI	A "Notice of References Cited" from the USPTO for U.S. application 09/773,604.	
	AJ	A "Notice of References Cited" from the USPTO for U.S. application 09/773,659.	
	AK	A "Notice of References Cited" from the USPTO for U.S. application 09/773,672.	
	AL	A "Notice of References Cited" from the USPTO for U.S. application 09/773,675.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/09A (08-00)

Approved for use through 10/31/2002. OMB 0851-0034
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/086,417
		Filing Date	March 4, 2002
		First Named Inventor	Bernd Riedl et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	BAYER 16P4
Sheet	7	of	8

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue-number(s), publisher, city and/or country where published.	T ²
	AM	A "Notice of References Cited" from the USPTO for U.S. application 09/776,935.	
	AN	A "Notice of References Cited" from the USPTO for U.S. application 09/776,936.	
	AO	A "Notice of References Cited" from the USPTO for U.S. application 09/777,920.	
	AP	A "Notice of References Cited" from the USPTO for U.S. application 09/946,915.	
	AQ	A "Notice of References Cited" from the USPTO for U.S. application 10/042,226.	
	AR	A "Notice of References Cited" from the EPO for European application EP 98/963809.	
	AS	Supplemental search report from the EPO for European application EP 98/963810.	
	AT	Supplemental search report from the EPO for European application EP 98/965981.	
	AU	Supplemental search report from the EPO for European application EP 00/903239.	
	BA	International search report for International Application No. PCT/US98/10375.	
	BS	International search report for International Application No. PCT/US98/10376.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb

K:\Bayer\25A\refs cited ids 10-29-02.doc

Please type a plus sign (+) inside this box:



PTO/SB/05A (05-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 8

Complete if Known

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Beind Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER 16P4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BC	International search report for International Application No. PCT/US98/26078.	
	BD	International search report for International Application No. PCT/US98/26079.	
	BE	International search report for International Application No. PCT/US98/26080.	
	BF	International search report for International Application No. PCT/US98/26081.	
	BG	International search report for International Application No. PCT/US98/26082.	
	BH	International search report for International Application No. PCT/US98/24265.	
	BI	International search report for International Application No. PCT/US00/00648.	
	BJ	International search report for International Application No. PCT/US00/00768.	
	BK	International search report for International Application No. PCT/US02/12064.	
	BL	International search report for International Application No. PCT/US02/12066.	
	BM	International search report for International Application No. PCT/US/26081.	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/vb

K:\Bayer\25Arefs cited kds 10-29-02.doc